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Angiotensin-I converting enzyme (ACE) is an important drug target in the treatment 
of heart disease due to its role in the regulation of blood pressure. ACE contains two 
domains, the N- and C-domains, both of which are catalytically active and heavily 
glycosylated. Glycosylation is one of the most important forms of post-translational 
modification, having a wide range of functions including protein folding, modulation of 
the immune response, and providing targeting signals. Glycosylation is required for 
the expression of active ACE and structural studies of ACE have been fraught with 
severe difficulties because of surface N-glycosylation of the protein. This problem 
has been addressed to a large extent with respect to the C-domain, where the role of 
glycosylation has been extensively characterised and a minimally glycosylated form 
was able to crystallise reproducibly. As yet, little is known about the degree and 
importance of N-linked glycosylation on the N-domain. The generation of minimally 
glycosylated N-domain, however, requires a greater understanding of the relative 
importance of the individual N-linked glycosylation sites. 
 
In order to determine the role of gl cosylation and to create suitable forms of the  
N-domain for crystallization studies, the ten potential N-linked glycan sites on the  
N-domain were investigated. Glycan site occupancy was assessed using enzymatic 
deglycosylation, limited proteolysis and mass spectrometry. A number of 
glycosylation mutants were generated via site-directed mutagenesis and expressed 
in CHO cells. The expression of active N-domain protein was analysed by an 
enzymatic activity assay and by Western blotting. The effect of glycosylation on 
thermal stability was assessed by determining the level of residual activity after 
thermal denaturation as well as by circular dichroism spectroscopy. In this way the 
various active glycosylation mutants were assessed and compared to wild type N-
domain. Nine out of the ten potential N-glycan sites were found to be glycosylated, 
while only site 10 was found to be unglycosylated. The presence of three C-terminal 
glycosylation sites was sufficient for the expression of active N-domain, although an 
N-terminal site with two of the C-terminal sites was also found to be effective. 
















stability, however, two N-terminal sites, sites 2 and 3, were found to be critically 
important for thermal stability.  
 
Thus, C-terminal glycosylation was found to play a key role in the expression of 
active N-domain, while N-terminal glycosylation was required for thermal stability. 
Additionally, the minimally glycosylated N-domain variant, Ndom389 (containing 
glycosylation at sites 3, 8 and 9), was highly suitable for crystallization studies, and 
the structure of this variant was solved to 2.0 Ǻ resolution in the presence of an  
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Chapter 1 : Introduction 
 
 
1.1 Angiotensin-I converting enzyme (ACE) 
Angiotensin-I converting enzyme is a membrane-bound dipeptidyl carboxypeptidase 
with an extra cellular orientation 1. ACE is an important biological catalyst with a 
number of diverse functions and occurs as two distinct isoforms: somatic ACE (sACE) 
and testis ACE (tACE). Somatic ACE contains two highly homologous domains, 
termed the N- and C-domains, and is expressed mainly in the vascular endothelial 
cells of the lungs, heart and kidney and brush border membranes of the kidneys and 
intestines 2-4. Testis ACE consists of the C-domain portion of sACE and is only 
expressed in male germinal cells 1,5,6. A naturally occurring N-domain isoform has 
been detected in ileal fluid, and is thought to arise from a proteolytic cleavage event 
in the region linking the N- and C-domains of sACE 7,8. The N- and C-domains both 
contain a functional zinc binding active site and share a high degree of overall 
sequence identity, approximately 60% 1, yet despite this, subtle variations at key 
active-site residues mean that the two domains have notable differences with regard 
to substrate and inhibitor selectivity. 
 
1.1.1 ACE gene structure 
The ACE gene is located on chromosome 17q23.3 and contains a total of 26 exons 
and two promoters (Figure 1.1) 9,10. Somatic ACE contains 25 of the 26 exons, with 
exon 13, coding for a heavily O-glycosylated region, being spliced out during mRNA 
processing 10,11. Testis ACE extends from exons 13 to 26 and is expressed off an 
alternate promoter located in intron 12, which is only activated in male germinal  




















Figure 1.1: Structure of the ACE gene. Relative positions of exons, promoters and 
domains are indicated (Adapted from Hubert et al. 1991) 
 
1.1.2 Biological roles of ACE 
1.1.2.1 ACE and hypertension 
Hypertension is one of the main causes of cardiovascular disease (CVD) 14, which is 
itself one of the main causes of morbidity and mortality worldwide, with up to 30% of 
all deaths attributable to CVD 15,16. Hypertension is said to be the most important 
treatable factor with regard to the prevention of cardiovascular diseases such as 
myocardial infarction, stroke, heart failure and related renal diseases 15,17,18. CVD is 
an important health concern, especially for developing countries where the burden of 
these diseases is greatest due to the large population sizes and poor access to 
public health facilities and treatments 15. Investing resources into treatment and 
prevention strategies should be a matter of priority for these countries which often 
overlook the importance of CVD due to the high profile of infectious disease such as 
HIV-AIDS and TB.  
 
The most celebrated role of ACE is its action in the renin angiotensin (RAS) and 
kallikrien-kinin (KKS) systems, where it plays an important role in the regulation of 
















peptide angiotensin II (AngII), while bradykinin (BK), a vasodilatory peptide, is 




Figure 1.2: Diagram showing the role of ACE in the RAS and KKS. ACE cleaves AngI to 
the vasoactive AngII eliciting vasoconstriction. ACE cleaves the vasoactive peptide BK to an 
inactive form (BK1-7), causing decreased vasodilation. The point of action of ACE inhibitors 
are indicated. 
 
Recent findings indicate that the major site of AngI cleavage is at the C-domain 
active site, while both domains cleave BK with equal efficiency 19-23. This finding has 
given rise to the pursuit of C-domain selective inhibitors, which are likely to provide 
control of blood pressure, while leaving the N-domain active to prevent BK 
accumulation, the accumulation of which is associated with some of the side effects 
of chronic ACE inhibition 1,24-27. 
 
1.1.2.2 The biological role of the N-domain of sACE 
Somatic ACE is able to cleave a wide range of substrates, including angiotensin-I, 
bradykinin, substance-P, gonadotropin-releasing hormone (GnRH), N-acetyl-Ser-
Asp-Lys-Pro (AcSDKP), angiotensin 1-7 (Ang1-7) and amyloid -β protein1-42  
 (A-beta42). Of these substrates, the N-domain has been show to be the main site of 

















The AngII-derived peptide, Ang1-7, elicits vasodilatory effects upon binding the 
Ang1-7 receptor. The N-domain is able to cleave Ang1-7 converting it to the inactive 
form (Ang1-5). This Ang1-7 degrading activity adds another means of ACE mediated 
blood pressure regulation through the RAS pathway 29. 
 
The N-domain is known to cleave abeta42, producing the shorter A-beta40 peptide 
and consequently, ACE inhibition has been shown to increase abeta42 levels 30,31.  
A recent review of a number of randomised controlled clinical trials has shown that 
treatment with ACE inhibitors, as well as diuretics, resulted in improved outcomes for 
patients suffering from various forms of dementia, including Alzheimer’s, although 
the exact mechanism for this is not clear 32. 
 
GnRH, is a short peptide hormone which instigates the release of follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) from the pituitary gland and is 
important for sexual maturation and reproductive function. Results have shown that 
LHRH is inactivated by ACE, and that cleavage is preferentially carried out by the  
N-domain 33-35. 
 
Perhaps the most important N-domain specific substrate, Ac-SDKP, was first 
identified as a regulatory peptide involved in hematopoietic stem cell proliferation 36, 
but has also been show to have a number of beneficial effects on the cardiac system. 
These include preventing or reversing cardiac, vascular and renal inflammation and 
fibrosis 37. Ac-SDKP mediates these effects, in part, by inhibiting macrophage 
differentiation, activation, migration and cytokine release. Ac-SDKP has also been 
shown to prevent end-organ damage resulting from hypertension 38, as well as 
protecting against diabetic cardiomyopathy 39. Additionally, increased levels of 
AcSDKP, following ACE inhibition, are thought to contribute to the beneficial effects 
of ACE inhibitors by a novel mechanism whereby AcSDKP inhibits collagen 
deposition in the left ventricle of the heart following vascular injury 40. N-domain 
knock-out mice, and mice undergoing chronic ACE inhibitor treatment, have 
AcSDKP levels six to seven times that of wild-type (WT) mice 41,42 22,41, illustrating 

















Thus, these findings highlight the need for the development of inhibitors selective for 
the N-domain of ACE which may prove useful in the treatment of certain diseases 
such as renal and pulmonary fibrosis, where inhibition of the N-domain would be 
beneficial, while the C-domain would remain active to allow for normal regulation of 
blood pressure. 
 
1.1.3 ACE inhibitors 
ACE inhibitors have long been used in the treatment of hypertension. A number of 
ACE inhibitors are currently on the market, with the peptide analogue, lisinopril being 
widely used. ACE inhibitors currently available to clinicians do not significantly 
discriminate between the two domains and were largely produced before the 
different roles of the two domains of sACE had been identified. Conventional ACE 
inhibitors are commonly associated with side effects such as loss of taste, skin rash, 
persistent coughing and angioedema 1,43-46. The first two side-effects are mainly 
attributed to the sulfhydryl inhibitors such as captopril, accounting for the decline in 
the use of this class of ACE inhibitor 1,25,47. Persistent cough is the most common 
side effect, affecting up to 20% of patients, while the occurrence of the potentially 
fatal angioedema is rare in the general population, affecting up to 0.5% of patients 
1,25,47. These adverse effects have largely been attributed to the accumulation of BK 
47. Thus an exciting shift in the development of ACE inhibitors is the generation of  
C-domain selective inhibitors, as it has been postulated that these will result in 
sufficient inhibition of sACE to reduce hypertension, while allowing the N-domain to 
remain active, thus prevent the excessive accumulation of BK and the associated 
side effects 1,24-27. At present there are no commercially available domain selective 
inhibitors, although certain inhibitors which show high levels of domain selectivity 
have been identified. These include the phosphinic inhibitors, RXPA380, an inhibitor 
which is 3000-fold more C-domain selective, and RXP407 which is  
1000-fold more selective for the N-domain (Figure 1.3) 1,48. RXP407, however, is not 



















Figure 1.3: Chemical structure of the N- and C-domain selective ACE inhibitors 
RXP407 and RXPA380. 
 
1.2 Protein glycosylation 
Glycosylation is a highly important form of post-translational modification in 
eukaryotic systems and has been shown to play a role in numerous, crucial cellular 
functions 49,50. The importance of protein glycosylation is further highlighted by the 
fact that 50% of eukaryotic proteins are predicted to be glycosylated, with 90% of 
these containing N-linked glycans 51. 
 
1.2.1 Types of glycosylation 
Enzymatic glycosylation of polypeptides occurs in two forms, namely: O-linked and 
N-linked glycosylation. O-linked glycosylation varies greatly, but generally, the glycan 
is attached via the linking of an N-acetylgalactosamine to the oxygen atom in the 
side chain of a serine (Ser) or threonine (Thr) residue 52,53. In N-linked glycosylation, 
attachment is via an N-acetylglucosamine residue linked to the nitrogen on the side 
chain of an asparagine (Asn) residue of the Asn-Xaa-Ser/Thr sequon (where Xaa is 
any amino acid except proline (Pro)) 54. Attachment of N-linked glycans is carried out 
co-translationally by the oligosaccharidal transferase complex (OST). N-linked 
















occur much more frequently and are also thought to play a greater role in protein 
folding and function 52. 
 
1.2.1.1 Types of N-linked glycosylation 
N-linked glycans fall into three general categories: high mannose, complex and 
hybrid glycans (Figure 1.4).  
 
High-mannose glycans are so called because they are largely comprised of 
mannose residues. These glycans are generally made up of a pentasaccharide core 
(two N-acetyl glucosamines (GlcNAc), followed by three mannose resides in a 
branched formation), plus a varying number of branched mannose residues 53. 
 
Complex glycans generally contain two GlcNAc residues, two galactose and up to 
two sialic acid resides, with one fucose sometimes attached to the first GlcNAc, in 
addition to the pentasaccharide core. However, the composition of complex glycans 
may vary considerably and are largely determined by the presence of specific 
glycosyltransferases in the medial and trans faces of the Golgi 53. 
 
Hybrid glycans are comprised mainly of mannose residues, but also contain a 
number of other sugars. These glycans contain the pentasaccharide core, with the 
addition of a few mannose residues, but are also prone to the addition of fucose, 
galactose, GlcNAc and sialic acid residues, although addition is generally restricted 



















Figure 1.4: Structures of O- and N-linked glycans. Blue squares show GlcNac; Green 
circles depict mannose; Yellow circles indicate galactose; Red triangles indicate fucose, 
Purple diamonds show sialic acid residues; Yellow squares indicate N-acetyl galactosamine. 
 
1.2.2 Requirements for protein glycosylation  
While most proteins which contain N-linked sequons have some level of 
glycosylation, many proteins have more than one potential glycosylation site and not 
all of these are necessarily glycosylated. Analysis of glycoproteins in the curated 
SWISS-PROT database revealed that on average, N-linked sequon occupancy is 
close to 66% 51. There are a number of reasons why N-linked sequons are not 
always glycosylated. These include the rate of protein folding, the subunit 
composition of the OST, the location of the sequon on the polypeptide chain and 
most notably, the sequence of the residues surrounding the glycan sequon 50. 
Binding of the OST to the growing polypeptide requires the fulfilment of a set of 
highly specific steric constraints. These constraints are accommodated by the classic 
















additional structural or sequence requirements appear to be critical for glycosylation, 
however, the presence of a Pro residue at the Xaa site (Asn-Pro-Ser/Thr),  
or immediately following the glycan sequon (Asn-Xaa-Ser/Thr-Pro), is known to 
prevent glycosylation 56. In addition, the residues at positions close to the sequon are 
able to positively or negatively modulate the likelihood of glycosylation at a particular 
site 50,55,57. A number of studies have examined this phenomenon and the results 
show that certain residues at positions Xaa-2, Xaa-1, Xaa and Xaa
+1 in the sequence 
Xaa-2-Xaa-1-Asn-Xaa-Ser/Thr-Xaa+1 are able to influence the likelihood of whether a 
sequon will be glycosylated or not 49,57-62. A recent analysis of over 25000 
glycoproteins containing over 2500 experimentally annotated glycosylation sites has 
revealed that in addition to the sequence of residues surrounding the glycosylation 
sequon, the distance of the sequon from the C-terminus also has a significant effect 
on sequon usage 63. Additionally, since glycosylation occurs co-translationally, 
glycosylation of a particular site is likely to be limited to those sequons that are able 
to achieve favourable conformations, enabling the glycan to be transferred to the 
growing polypeptide through short-range interactions with the OST 55.  
 
1.2.3 Glycosylation and protein folding 
As mentioned, N-glycosylation occurs co-translationally, before a significant degree 
of folding can take place, meaning that the timing of protein glycosylation allows for it 
to have a significant effect on protein folding 64-66. Without doubt, assisting the folding 
of proteins in the endoplasmic reticulum (ER) is one of the most important functions 
of N-linked glycosylation in eukaryotes 67-69. It is well established that glycosylation is 
required for a number of proteins to fold correctly. Interestingly there are a number of 
ways in which glycans are able to carry out this function, affecting both local and 
global structure stability, as well as playing an important role in the targeting of 
misfolded proteins for degradation. 
 
1.2.3.1 Direct effects of glycosylation on protein folding 
N-linked glycans are known to have a direct effect on protein folding 54,68,70. An 
elegant study using polypeptide fragments with and without glycosylation sites has 
shown that the attachment of a glycan to a polypeptide fragment can promote a 
conformational shift 71. This shift was able to cause the peptide to adopt a more 
















protein. This effect was not seen with the unglycosylated peptides. It is proposed that 
these conformational shifts could act as “nucleation” events, limiting the transition to 
certain (possibly unfavourable) conformations, while making the adoption of others 
possible, thereby forcing the protein through a particular folding pathway. This is 
important since protein folding occurs rapidly, thus requiring certain mechanisms to 
streamline the folding process and thereby prevent the aggregation of unfolded or 
partially folded proteins 71,72. Furthermore, interactions between the first few glycan 
residues of the attached glycan and the polypeptide backbone are able to promote 
the formation of β–turns, a key structural motif, further highlighting the direct role 
glycans play in the folding process 50,73. The hydrophilic polysaccharides on the 
protein backbone are also able to promote folding by orientating the sequence 
proximal to the attached glycan towards the surface of the protein structure. This 
effect is a result of the thermodynamic force of entropy: the hydrophobic regions of a 
protein tend to orient themselves to the internal region of the protein where they can 
interact with other hydrophobic residues, thus being isolated from the polar solution 
surrounding the protein. In contrast, the hydrophilic regions are positioned such that 
they are located on the outer surface of the protein, enabling interactions with the 
polar environment of the ER. Thus, the attachment of hydrophilic glycans to the 
protein can alter the hydrophobicity of a specific region of the sequence, affecting its 
orientation as the protein folds 68. In many instances the location of the glycosylation 
site(s) is important, although there often exists a level of redundancy, such that the 
importance of a particular site may only be revealed when other sites are removed 68. 
 
1.2.3.2 Indirect effects of glycosylation on folding 
1.2.3.2.1 Glycosylation and the calnexin and calreticulin cycle 
The calnexin-calreticulin cycle is probably the most significant aspect of glycosylation 
mediated folding of glycoproteins 50. The calnexin-calreticulin story begins with the 
attachment of the glycan chain to the growing polypeptide in the ER. This glycan 
chain consists of the classical pentasaccharide core plus a further six mannose 
residues, forming a branched structure. This heavily mannosidated structure is 
capped by three glucose residues attached to one branch of the glycan chain 50. 
These glucose residues provide the key to the calnexin-calreticulin cycle. The first 
two glucose residues are cleaved off by glucosidase-I and II in a stepwise fashion 
















subsequently removed by glucosidase-II and reattached by the glucosyltransferase 
in a cyclic fashion 67,77,78. The cyclic removal and reattachment of this glucose 
residue is critical for the cells protein-folding quality control system as glycoprotein 
binding to the lectin chaperones calnexin and calreticulin is dependent on the 




Figure 1.5: Diagram of glycoprotein folding via the calnexin-calreticulin cycle. 1) 
Monoglucosylated proteins bind to calnexin (CNX) and calreticulin (CRT), 2) which assist 
glycoprotein complex formation with ERp57, enabling correct disulfide bond formation. 3) 
Correctly folded proteins are translocated to the golgi by ERGIC-53, VIP36 or VIPL. 4) 
Missfolded proteins are demannosylated by ER manosidase-1 and translocated to the 
cytoplasm by EDEM, 5) for degradation by the ERAD pathway (Adapted from Helenius 
2004). 
 
Typically, the monoglucosylated glycoprotein binds to calnexin or calreticulin 78, 
which facilitates the formation of a complex with ER protein 57 (ERp57), a  
thiol-disulfide oxidoreductase. ERp57 assists disulfide bond formation, enabling the 

















Proteins which have achieved their correct conformation are not recognised by the 
glucosyltransferase, and thus remain unglucosylated, exiting the calnexin-calreticulin 
cycle 80. These proteins are then free to be translocated to the golgi with the 
assistance of ER golgi intermediate compartment (ERGIC-53), vesicular integral 
protein 36 (VIP36) or VIP36-like protein (VIPL) 50,79.  
 
Protein which have failed to fold correctly are targeted for degradation 50. This occurs 
when the misfolded glycoprotein is acted on by the ER manosidase-1. The removal 
of a single terminal mannose residue from the glycan chain allows the misfolded 
protein to bind the ER degradation enhancing α-mannosidase-like protein (EDEM). 
EDEM facilitates translocation of the misfolded protein to the cytosol for degradation 
as part of the ER associated degradation pathway (ERAD), thereby preventing the 
accumulation of misfolded proteins in the ER 50,81. Thus, the ERAD pathway, and the 
controls regulating it, are elegantly designed to provide a critical means of removing 
misfolded proteins from the ER, without exposing resident proteins to unwanted 
proteolysis 50. 
 
1.2.3.2.2 The influence of glycosylation on protein solubility and aggregation 
The importance of glycosylation with respect to improving the solubility of a folding 
protein has more to do with the presence of the glycans and less to do with their 
location. Folding intermediates generally have a higher hydrophobicity profile as 
compared to the fully folded protein 67. This is because the majority of the 
hydrophobic residues are orientated towards the interior of the protein in the folded 
state while, in contrast, they are exposed to the solvent during the folding process. 
The exposed hydrophobic regions of a polypeptide intrinsically prefer to interact with 
other hydrophobic residues in the polar environment of the cell, due to the lower 
state of entropy this induces. Thus, the presence of large polar glycans on the 
polypeptide chain are a convenient way for the cell to reduce the hydrophobicity of 
the folding intermediates, thereby increasing their solubility and reducing the 
likelihood of irreversible protein aggregation 54,67. These factors allow the folding 
intermediates a greater chance of achieving the correct conformation than would 

















In summary, glycosylation assists protein folding by direct and indirect means and 
although often critical for the correct folding of glycoproteins, the glycans are 
generally not needed for maintaining the structure once the protein has folded, as 
evidenced by the fact that removal of the attached glycans does not affect protein 
structure or function in a number of cases 54,67,68,82. However, some proteins do 
require the presence of glycans to retain their folded state and biological function, as 
is the case with human CD2 protein 67,83. In short, some proteins are dependent on 
attached glycans for folding, while some are able to fold regardless of whether 
glycans are attached or not. Some proteins are dependent on glycosylation only in 
certain cell types 84, while others become temperature dependant for folding if the 
glycans are removed, only being able to fold correctly at lower temperatures 50,67,68,82.  
 
These findings highlight the fact that while glycosylation is critical for the folding of 
many glycopeptides, this is not always the case, and that even where it is, some 
glycosylation sites may be more important than others. Generally the more surface 
glycans present on a protein, the more dependent that protein is likely to be on 
glycosylation for folding 50.  
 
1.2.4 Glycosylation and proteolysis 
Protein glycosylation is known to retard proteolysis of a number of proteins, including 
deoxyribonuclease-1, butlycholinesterase, lactoferrin, fibronectin and saposin-B 85-89. 
There are two likely mechanisms for a glycan mediated increase in resistance to 
proteolysis. The attachment of glycans have, in some cases, been associated with 
the formation of β–turns in the protein structure proximal to the glycan site and may 
provide conformational rigidity at these β–turns 52,90, making the protein a poorer 
substrate for proteases 88. Alternatively, the presence of bulky N-linked glycans is 
thought to shield potential protease recognition sites on the surface of the protein 
82,85-87, thus increasing the half life of the protein by reducing protease access. 
 
1.2.5 Glycosylation and protein-protein interactions 
Glycosylation is known to play a role in protein-protein interactions. This is most 
notably evidenced by the fact that the ability to bind sugars categorises an entire 
protein family, termed lectins, of which calnexin and calreticulin are classic examples. 
















biological processes ranging from protein folding, immune response and fertilisation 
to cell-cell and cell-matrix adhesion, amongst others 91,92. 
 
An important aspect of glycan mediated protein-protein interactions is the 
phenomenon of dimerisation and oligomerisation. The formation of dimers and 
oligomers is critical to the functioning of certain proteins 93-95. Glycans can promote 
the formation of dimers in a number of ways. Firstly, glycans have been shown to 
facilitate protein dimerisation by mediating direct interactions with the protein 
backbone of the other subunit(s), thus stabilising the dimer (or oligomer) and holding 
the various subunits together 52,96. Additionally, evidence suggests that for certain 
proteins, folding is rapidly followed by oligomerisation 67. Indeed, numerous proteins 
have been shown to oligomerise while attached to calnexin 67,78,97-100. In these cases 
it would seem that glycosylation plays an indirect role in the formation of the 
oligomers by facilitating polypeptide binding to calnexin, which allows multiple 
subunits to fold in close proximity to one another, thereby promoting subunit 
assembly into dimer or oligomer complexes 67. 
 
1.2.6 Glycosylation and thermal stability 
The thermal stability of proteins is a topic of much interest, particularly in the context 
of the biotechnology industry, where higher temperatures generally relate to 
increased reaction rates 101. There are a number of methods for analysing the 
thermal stability of proteins. The three most commonly used methods include Fourier 
transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and 
circular dichroism (CD) spectroscopy 102.  
 
Thermal stability analysis of total protein from mammalian cells show that proteins 
vary greatly in their degree of thermal stability, with melting temperatures (Tm) 
ranging from about 40 °C to 90 °C 102,103. This high degree of variability in the level of 
thermal stability for different proteins can be due to a number of factors. These 
factors include α-helical content, hydrophobicity, the level of internal packing and 
aromatic clustering, the number of ion pair interactions, proline content, as well as 
the presence of disulfide and salt bridges 104-106. In addition, N-linked glycosylation is 
also able to provide proteins with increased resistance to thermal stress. It is thought 
















interactions between the glycans and the residues on the surface of the protein 
52,67,82,85. Various studies have shown that deglycosylated, or unglycosylated, forms 
of certain proteins have reduced thermal stabilities compared to their fully 
glycosylated counterparts, as is the case for proteins such as deoxyribonuclease-1, 
immunoglobulin G1 and cathepsin E 
85,107,108.  
 
1.2.7 Glycosylation and protein crystal structure determination 
Glycosylation presents a major obstacle to protein crystallography. This is because 
the glycans attached to the protein surface are bulky, flexible and often of 
heterogeneous in composition, thus interfering with crystal packing by disrupting the 
protein-crystal forming surfaces 109-111. However, glycosylation is a vital form of post-
translational modification and is often a requirement for correct folding and 
processing 67, as is the case with ACE 112.  
 
There are a number of methods to circumvent this dilemma: Firstly, non-mammalian 
expression systems such as expression in yeast and insect cells may be used. 
These systems have the advantage of possessing simpler glycosylation pathways, 
resulting in a reduced level of sample heterogeneity, something which is beneficial 
for protein crystallisation 109-111. However, insect cell culture is costly and is often 
associated with technical difficulties, while a number of glycoproteins fail to fold 
correctly in insect and yeast cells or require complex glycosylation for proper function 
113,114. The failure of glycoproteins to fold correctly in these systems can be corrected 
by genetic manipulation, providing these systems with a humanised glycosylation 
pathway, although this does not aid crystallisation 113,114. In addition, folding 
problems related to expression in yeast cells can be overcome by exploiting the 
unfolded protein response pathway, which activates ERAD of glycoproteins 115. 
Recombinant protein overexpression is often used to generate large quantities of a 
protein of interest. However, this approach can saturate the cells expression 
machinery, leading to sharp increase in the amount of unfolded proteins and 
consequently activation of the ERAD pathway, thus leading to lower total yields. By 
adjusting the expression rate of the construct, by using different promoters, one is 
better able to match the expression of the protein of interest with the expression 
capacity of the cell, leading to a greater efficiency in the expression of correctly 
















by co-overexpression of folding chaperones, leading to a greater yield of folded 
protein 116. Another alternative is to express the protein in a glycosylation deficient 
mammalian cell line, such as Chinese hamster ovary (CHO) Lec 3.2.8.1 cells, which 
produce only high mannose glycans 117,118. However, poor protein yields from  
Lec 3.2.8.1 cells is a drawback to this approach. Furthermore, while these systems 
are useful for the expression of glycoproteins, the level of glycan heterogeneity can 
still be problematic for crystallisation studies. 
 
Problems associated with glycan complexity can be overcome by enzymatic 
deglycosylation of the purified protein 119, although this requires re-purification of the 
target protein and deglycosylation is not always 100% efficient. Alternatively, 
expressing the protein of interest in the presence of glycosylation inhibitors such as 
tunicamycin, swainosin, kifunensin and N-butyl deoxynojirimycin (NB-DNJ) 117, have 
been used to reduce the level of protein glycosylation 109. The use of tunicamycin 
however is not suitable for the expression of all glycoproteins, as this inhibitor 
prevents dolichol oligosaccharide precursor synthesis, thus eliminating all N-linked 
glycosylation 67,120. NB-DNJ inhibits α-glucosidase I and II, preventing cleavage of 
the three terminal glucose residues from the core oligosaccharide structure, thus, 
blocking further glycosylation from taking place and leaving the attached glycans in a 
high mannose state 109. Swainosin and kifunensin are α-mannosidase inhibitors and 
generally allow for better protein yields than NB-DNJ since they act downstream of 
the folding pathway 117. The use of glycosylation inhibitors has been successful, 
particularly when combined with an enzymatic deglycosylation step, typically 
involving endogylcosidase-H 117, although complete inhibition of the glycosylation 
machinary is not always achieved, meaning that a degree of glycan complexity and 
heterogeneity may still exist after treatment 109. Attempts to address this problem 
have focussed on combining the use of the glycosylation deficient Lec 3.2.8.1 cells, 
with expression in the presence of a glycosidase inhibitor. This approach has proved 
successful in reducing the glycan complexity and heterogeneity and allowing the 
production of proteins suitable for crystallisation 109, although expression levels are 
often very low. Given the high protein concentrations required for protein 


















Alternatively, to prevent the formation of large, complex glycans on the surface of the 
protein, or their removal by laborious means, a minimally glycosylated protein can be 
engineered. This involves determining which of the potential glycosylation sites 
present on the surface of the protein are actually required for correct folding. This is 
achieved by sequentially disrupting the N-glycosylation sequons using site-directed 
mutagenesis, where the Asn of the Asn-Xaa-Ser/Thr glycosylation sequon is 
mutated to a glutamine (Gln). This conservative mutation eliminates OST recognition 
of the sequon, while preserving the physical properties of the sequence. This method 
has been used successfully to generate proteins amenable to crystallisation in a 
number of cases 121-123. The benefit of this method is that once set up, the 
expression-to-crystallisation pipeline contains relatively few steps, allowing for a high 
throughput approach to be employed. This is beneficial particularly in cases where 
the rational design of domain selective inhibitors is being sought, allowing numerous 
potential inhibitors to be crystallised and the interactions optimised based on the 
data from the X-ray crystal structure. 
 
1.3 Glycosylation of ACE 
Human ACE is a heavily glycosylated protein, approximately 30% by weight, and 
contains a total of 17 N-linked glycosylation sites 1,7,124, with ten of these being 
located in the N-domain. Studies on the C-domain (tACE), recombinantly expressed 
in CHO cells, have shown that of the seven potential sites on this domain, the three 
N-terminal sites (sites 1, 2 and 3) are always glycosylated, while the following three 
sites (sites 4, 5 and 6) are glycosylated with partial efficiency, being found in both the 
glycosylated and unglycosylated forms. Site 7 was found to be unglycosylated in all 
instances 124. Analysis of sACE, purified from human kidney cells, showed that 
glycosylation was present at sites 1, 2, 4, 5 and 9 of the N-domain, while only site 5 
(N913) of the C-domain was glycosylated 124 (Figure 1.6). While this study did not 
detect glycosylation at a number of potential N-linked sites on both the N- and  
C-domains of sACE, this does not automatically imply that they are unglycosylated. 
Nevertheless, analysis based on calculations of the mass contribution of the glycans 
to sACE indicate that approximately seven to eight sites are glycosylated 84, 




















Figure 1.6: Glycosylation of the N- and C-domains of sACE. N-linked glycosylation sites 
on the N- and C-domains shown as boxes. Black boxes indicate sites which are glycosylated, 
white boxes depict sites with unidentified glycosylation status and grey boxes indicate 
sequons found to be unglycosylated. Glycosylation sites are numbered according to the 
sequence of the individual domains. 
 
Additionally, Yu et al. (1997) analysed the sequence of the attached glycans on 
tACE. This was achieved using mass spectrometry to analyse the masses of 
digested peptides, treated with and without protein N-glycosidase-F (PNGase-F), 
which removes N-linked glycans. Observed masses corresponding to the sum of a 
glycopeptide mass, plus that of a theoretical glycan, were identified in a number of 
cases, but not after PNGase-F treatment, indicating that those masses were the 
result of glycan attachment to potential glycopeptides. From these data they were 
able to predict the composition of the glycans. Their results show that tACE 
expressed in CHO cells contain mostly biantennary, fucosylated complex glycans, 
with either one or two terminal sialic acid residues (as per the structure of complex 
glycans indicated in Figure 1.4). It is expected that the glycans of the N-domain and 
sACE would fall into a similar category. 
 
1.3.1 Glycosylation requirements for ACE expression 
Glycosylation is known to be important for the correct folding of ACE proteins. When 
tACE was expressed in bacterial cells lacking glycosylation machinery, only inactive 
protein was produced 112. Additionally, when tACE was expressed in HeLa cells in 
the presence of tunicamycin (which prevents the attachment of N-linked glycans), or 
when all of the N-linked glycosylation sites were mutated, expressed tACE proteins 
















expression of recombinant N-domain, inactive protein was produced when a number 
of the N-linked glycosylation sites were mutated 125. 
 
Extensive site-directed mutagenesis of the N-glycosylation sites on human tACE has 
revealed that glycosylation of only site 1 or 3 is needed for the production of active 
protein 122. These findings correlate with those of Yu et al. (1997), which showed that 
the three N-terminal sites were always glycosylated, while the remaining sites were 
either found to be unglycosylated, or were glycosylated with partial efficiency, 
highlighting the presence of a selective pressure on the N-terminal sites. Studies on 
rabbit tACE, revealed that only sites 1 or 2 were required for expression of functional 
protein, while site 3 alone was not sufficient. However, when expressed in yeast cells, 
glycosylation at site 3 alone was sufficient to allow for correct folding, indicating that 
the exact glycosylation requirements vary between different cell types and culture 
systems 112. These findings again highlight the importance of N-glycosylation for the 
correct folding and processing of ACE proteins.  
 
While glycosylation is essential for the folding and expression of active ACE proteins, 
studies have shown that if the attached glycans are enzymatically removed under 
native conditions, the protein retains its activity, displaying catalytic constants 
comparable to that of the fully glycosylated protein 124. Similarly, when varying 
numbers of the N-glycosylation sites were mutated by site-directed mutagenesis, the 
catalytic constants for substrate hydrolysis remained within the same range 122. Thus, 
glycosylation does not seem to play a role in the enzymatic activity of ACE. 
 
1.3.2 ACE glycosylation and dimerisation  
Somatic ACE is known to occur as a monomer, but has also been shown to occur as 
a homodimer in a reverse micelle membrane model, as well as in cell culture 
experiments with CHO and endothelial cells 126,127. Somatic ACE also occurs as a 
soluble form, which is known to arise from a cleavage event at the “stalk” region, 
between the C-domain and the transmembrane domain, carried out by an as yet 
unidentified secretase 13,128,129. Dimerisation of sACE has been found to negatively 
influence shedding of the enzyme from the surface of CHO cells 130. Interestingly 
glycosylation has also been shown to affect the level of sACE shedding, with partially 
















compared to fully glycosylated sACE 131. The importance of this finding is evidenced 
by the fact that elevated levels of soluble sACE, resulting from increased cleavage of 
membrane bound sACE, have been associated with granulomatous disorders such 
as sarcoidosis 132. 
 
Currently two theories have been proposed for the mechanism of ACE dimerisation. 
The first suggests that dimerisation is mediated by glycans on the N-domain binding 
a putative carbohydrate recognition domain (CRD) also located on the N-domain 126. 
This is based on findings which showed that glycosylated sACE was able to form 
dimers, while this ability was lost after sACE was enzymatically deglycosylated with 
PNGase-F. In addition, Kost et al. (2000) showed that dimerisation could be inhibited 
by the addition of excess free glycans (specifically galactose and N-acetylneuraminic 
acid), as well as by the whole pool of sACE oligosaccharide chains. These data 
suggest that dimerisation is mediated by an interaction between certain sACE 
glycans and a CRD on the protein. The use of several monoclonal antibodies (mAbs) 
with differing epitopes allowed the localisation of this CRD to be mapped to the  
N-domain, as two mAbs directed to different, but overlapping regions of the  
N-domain were able to prevent carbohydrate mediated dimerisation 130.  
 
The second theory is based on data that showed an increased level of dimerisation 
after inhibitor treatment of endothelial cells, an effect which was not seen with a  
C-domain knock-out form of sACE 127. This suggests that ACE inhibitor binding to 
the C-domain of sACE promotes dimerisation as part of a signalling cascade leading 
to activation of the c-Jun kinase pathway 127. Thus it would seem that sACE is able 
to form dimers via two different mechanisms, one mediated by the N-domain and 
dependent on glycosylation and the other initiated by inhibitor binding to the  
C-domain of sACE. However, a role for glycosylation in inhibitor induced sACE 
dimerisation has not been ruled out 133. 
 
1.3.3 ACE glycosylation and thermal stability 
As mentioned previously, sACE contains two domains, the N- and C-domains. The 
N-domain is known to be the more stable of the two domains. This idea arose from 
observations that an N-domain fragment was present in ileal fluid, presumably due to 
















was not detected 7. Furthermore, in vitro digestion with the endoproteinase Asp-N 
was found to cleave the linker region between the two domains, while limited 
proteolysis with trypsin, plasmin or kallikrein was found to produce a truncated form 
of sACE corresponding to the N-domain 7,8. The greater stability of the N-domain 
was further demonstrated when it was shown that rat tACE was less thermally stable 
than the sACE form, indicating that the N-domain portion was providing increased 
stability to the sACE form 104,134. Denaturation studies have revealed that this was 
also the case for human ACE, with tACE being less stable than the sACE form 104,135. 
 
Differential scanning calorimetry (DSC) has revealed two distinct Tm values for sACE 
at 55 °C and 72 °C 104. Analysis of sACE, as well as the individual N-domain 
fragment, revealed that the higher Tm corresponds to that of the N-domain. It is 
interesting to note that the authors were able to selectively denature the C-domain of 
ACE by incubating sACE at 55 °C for 1hr, implying that the two domains are able to 
fold, or unfold, relatively independently of one another 104. 
 
Given the high degree of sequence and structural similarity between the two 
domains, it is surprising that they display such markedly different Tm values. A few 
reasons have been postulated to explain this difference in thermal stability, namely: 
a higher Pro content between amino acids 29-133 in the N-domain, compared to the 
equivalent region of the C-domain, potentially conferring a greater degree of 
structural rigidity; a slightly greater degree of α-helical formation and an increased 
level of N-linked glycosylation 104. Recently it has been shown that glycosylation 
plays a critical role in maintaining the thermal stability of the C-domain. Using circular 
dichroism to monitor the temperature at which the unfolding transition occurs, the 
thermal stability of various C-domain glycoforms were determined. It was found that 
decreasing levels of glycosylation correlated with a decrease in Tm, with the absence 
of four of the six glycosylated sites in tACE resulting in a lowering of the Tm by about 
8 °C 136. The effect of glycosylation on thermal stability was also noted in an ACE 
homologue, AnCE. Expression of an unglycosylated form of AnCE in yeast cells 
showed that glycosylation was important for maintaining thermal stability, although it 

















1.3.4 Glycosylation and the solution of ACE crystal structures 
The use of protein crystal structures solved in complex with specific inhibitors is a 
valuable tool for rational drug design. Given the importance of ACE inhibitors in the 
treatment of cardiovascular disease, the solution of the sACE crystal structure is an 
important pursuit. Attempts to crystallise sACE have as yet been unsuccessful, most 
likely due to the high level of glycosylation and the flexibility of the region joining the 
two domains of this enzyme. However, when faced with a complex problem, a 
deconstructionist approach often proves successful, and indeed success has been 
achieved in crystallising the individual domains of sACE.  
 
As is often the case with membrane bound glycoproteins, crystallisation of the 
individual domains of ACE has not been trivial. After initial attempts to crystallise 
tACE (equivalent to the C-domain of ACE) were unsuccessful, a truncated form was 
developed with the transmembrane region at the C-terminus, and a heavily  
O-glycosylated region at the N-terminus (not present in the C-domain of sACE), 
removed. This shortened, soluble form of the enzyme, expressed in the presence of 
NB-DNJ and treated with endoglycosidase-H (which leaves just a single GlcNAc 
residue attached to the Asn of the glycosylation sequon) was able to form 
diffractable crystals and led to the solution of the first X-ray crystal structure for 
human tACE 122,138. The solution of the N-domain structure was also hampered by 
the high degree of surface glycosylation and once again, expression in the presence 
of the glucosidase inhibitor NB-DNJ was required to produce a crystallisable form of 
the N-domain 139. Although the use of NB-DNJ allowed for the solution of the crystal 
structure for the N- and C-domains, crystallisation in both cases, was not 
reproducible, and combined with the high cost of the NB-DNJ, this approach was 
deemed unfeasible for routine use. 
 
To circumvent the problems associated with reproducible crystallisation and the use 
of expensive glycosylation inhibitors, attempts were made to produce forms of the  
N- and C-domains which contained the fewest possible number of intact 
glycosylation sites. This approach would reduce glycan complexity and avoid the 
need for expensive glycosylation inhibitors. Based on the glycosylation site 
occupancy of tACE, revealed by Yu et al. (1997), extensive site-directed 
















that glycosylation of only one or two of the N-terminal sites was required for 
expression of active protein 122. Using one of the hypoglycosylated forms of tACE 
(tACEg13), reproducible crystal formation was achieved 140. An alignment of the two 
C-domain crystal structures (using PyMOL v0.92), shows that they are essentially 
identical, with a root-mean square deviation (RMSD) of 0.19 Å for all atoms, 
indicating that mutation of the glycan sequons did not affect the structure of the 




Figure 1.7: Comparison of the crystal structures of the C-domain for the glycosylation 
WT (tACE) (light blue) and minimally glycosylated forms (tACEg13) (Green). N- and  
C-termini labelled purple and red respectively. Lisinopril (yellow), bound to the active site 
zinc (grey) is shown. Figure was drawn with PyMOL v0.92 using the PDB structures 1O86 
and 2IUL 138,140 (DeLano Scientific, San Carlos, CA, USA). 
 
Given the high degree of structural similarity between the N- and C-domains (RMSD 
of 0.72 Å for all atoms) it is expected that the generation of a similarly 
hypoglycosylated form of the N-domain would be suitable for high throughput 
inhibitor-enzyme crystallisation studies. The generation of a minimally glycosylated 
N-domain however, requires a greater understanding of the relative importance of 

















1.4 Aims and objectives 
The effect of glycosylation on the C-domain has been well characterised, yet very 
little is known about the importance of glycosylation for the N-domain. This work 
aims to investigate the functional significance of the N-linked glycans and generate a 
form of the N-domain suitable for reproducible protein crystallisation. The generation 
of a readily crystallisable form of the N-domain will aid a high throughput approach to 
the rational design of N-domain selective inhibitors.  
 
To achieve these aims, the following objectives were identified: 
 
1. To determine the glycan site occupancy of the ten N-glycosylation sequons on 
the N-domain. 
2. To determine which glycosylation sites are required for expression of active 
N-domain protein. 
3. To examine the effect of glycosylation on the thermal stability of the N-domain. 
4. To generate minimally glycosylated N-domain variants for crystallisation trials 
and carry out kinetic analyses on these mutants. 
5. To combine minimally glycosylated N- and C-domains to generate a minimally 
glycosylated form of sACE 
6. To assess the expression, thermal stability and kinetic parameters of 



















Chapter 2 : Investigating the glycosylation site 




The glycosylation profile of the C-domain has been extensively investigated, with the 
glycosylation status of each site having been determined 124. Less is known about 
the glycosylation profile of the N-domain, although Yu et al. (1997) were able to 
identify the presence of glycosylation at sites 1, 2, 4, 5 and 9 on the N-domain of 
sACE purified from human kidney cells. However, this does not mean that the other 
sites were not glycosylated. While these sites were identified on the N-domain of full 
length sACE 124, the status of the ten potential glycosylation sites on recombinant  
N-domain, which has been used for structure determination, have not been 
characterised. This is important as the glycosylation site occupancy for the N-domain 
of full length sACE may not be identical to that of the N-domain expressed on its own. 
Indeed this was the case with the C-domain of sACE where only one site was found 
to be glycosylated, while up to six sites were glycosylated in the C-domain 
expressed on its own 124. Furthermore, it is well known that protein glycosylation can 
vary between different cell types 68,75. Since recombinant N-domain is commonly 
expressed in CHO cells, it may have a different glycosylation pattern to sACE 
purified from human kidney cells.  
 
Identifying which of the ten potential glycosylation sites on the N-domain are 
glycosylated is an important step toward understanding the effect(s) these glycans 
have on enzyme processing, expression, stability and kinetics. Profiling the 
glycosylation site occupancy of the N-domain is also the first step toward the 
generation of a minimally glycosylated N-domain variant suitable for high throughput 
inhibitor-enzyme crystallisation trails.  
 
The online prediction tool NetOGlyc 3.1 did not predict any O-linked glycosylation of 
the N-domain 141. There are however ten potential N-linked glycosylation sites on the 

















nine of these sites are likely to be glycosylated (Table 2.1). The NetNGlyc software 
makes use of “artificial neural networks” which are trained to recognise the amino 
acid sequence surrounding the sequons of sites whose glycosylation status in known. 
These patterns are then compared to imputed sequences. In this way the likelihood 
of sequon usage is calculated. This method reports an accuracy of approximately 




Table 2.1: The predicted likelihood of N-linked sequon usage for the N-domain of ACE. 
(Generated from the N-domain amino acid sequence (see Appendix Figure A1) using the 
NetNGlyc web tool 142). Glycosylation potential must exceed 0.5 for glycosylation to be 
predicted.  
 
We attempted to map the N-glycosylation sites of purified recombinant N-domain 
using mass spectrometry and enzymatic deglycosylation with peptide- 
N-glycosidase-F (PNGase-F). Since PNGase-F is an amidase, the Asn (114 Da) 
residue of the glycosylation sequon is deamidated to an Asp (115 Da) during the 
removal of an attached glycan. This increase in mass of 1 Da can be used to identify 
the presence of N-glycosylation at potential glycosylation sites using mass 
spectrometry. To generate peptides amenable to analysis by mass spectrometry, the 
deglycosylated protein was digested with either trypsin or endoproteinase Glu-C 

















glycosylation sequon, simplifying interpretation of the data. Thus, the resulting 
peptides were analyzed by MALDI-ToF/ToF, while deamidation of the Asn to Asp 





1. To determine which of the potential N-glycosylation sites on the N-domain are 
glycosylated, by identifying potential glycopeptides formed after tryptic or  























2.2 Experimental procedures 
2.2.1 Materials 
PNGase-F (proteomics grade), trypsin (modified, sequencing grade) and 
endoproteinase Glu-C (proteomics grade) were purchased from Sigma (MO, USA). 
 
2.2.2 Transfection and expression of N-domain in CHO cells  
Soluble recombinant human N-domain (Ndom629D), comprising the first 629 
residues of sACE, in the mammalian expression vector pcDNA3.1+ (Invitrogen, CA, 
USA) 143, was transfected into Chinese hamster ovary-K1 (CHO) cells using the 
CaPO4 method (ProFection® Mammalian Transfection Systems kit - Promega, WI, 
USA) as per the manufacturer’s instructions. Prior to transfection, CHO cells were 
grown in CHO growth medium (10% FCS, 43% DMEM, 43% F-12 HAMS, 20 mM 
HEPES pH 7.5) in 10 cm3 culture dishes (37 °C, 5% CO2) until approximately 50% 
confluent. Cells were incubated with fresh CHO growth medium for three hours prior 
to transfection. DNA-CaCl2 crystals were prepared by bubbling 10 μg DNA and  
248 mM CaCl2 through an equal volume of HEPES buffered saline (50 mM HEPES, 
280 mM NaCl, 1.5 mM Na2HPO4 pH 7.1), incubated at room temperature for 30 min 
and added drop-wise to the cells. After 4 hrs incubation at 37 °C cells were treated 
with 1 ml glycerol shock solution (15% (v/v) glycerol in 1x PBS) for 1 min. Glycerol 
was removed by washing with 1x PBS (137 mM NaCl, 2.7 mM KCl, 20 mM Na2HPO4, 
2 mM KH2PO4, pH 7.4). Cells were then incubated with CHO growth medium (37 °C, 
5% CO2) overnight, after which medium was replaced with CHO growth medium 
containing 0.8 mg/ml Geneticin (G418, Sigma). Antibiotic resistant colonies were 
picked into a 24 well culture plate using sterile swabs and grown until confluent. 
Twenty four hour medium was collected and assayed for ACE activity (described in 
Chapter 4.2.2). Active clones were lifted into T25 culture flasks using trypsin-EDTA 
(0.5% (w/v) Trypsin, 0.5 mM EDTA, 13 mM NaCl, 10 mM Na2HPO4.2H2O, 2.7 mM 
KCl, 1.5 mM KH2PO4.2H2O pH 7.4). Once confluent, cells were washed with 1x PBS, 
lifted with TEDTA and resuspended in 10% (v/v) DMSO in FCS for storage in liquid 
nitrogen. For bulk expression, cells were grown to confluence in T175 culture flasks 
and placed under CHO medium containing 2% FCS. Medium was harvested into 


















2.2.3 Purification of recombinant N-domain protein 
Soluble recombinant N-domain proteins were purified from conditioned medium by 
lisinopril-Sepharose affinity chromatography, as described previously 144, with the 
exception that the harvested medium and wash buffer were adjusted to 800 mM 
NaCl, to facilitate N-domain binding to the column 7. Briefly, purification columns 
were washed with 20 mM HEPES, 800 mM NaCl (pH 7.5) to remove unbound 
components. N-domain protein was eluted with 50 mM borate (pH 9.5). After 
purification, samples were dialysed against 2x 2 L 50 mM HEPES buffer (pH 7.5) 
(containing 0.1 mM PMSF protease inhibitor) at 4 °C and concentrated using 30 000 
kDa cutoff Amicon® Ultra spin centrifugal filters (Millipore, Cork, Ireland). Protein 
concentrations were determined by measuring absorbance at 280 nm on a 
Nanodrop® ND1000 using a molecular mass of 72 kDa and an extinction coefficient 
of 161877 M−1 cm−1. N-domain molecular mass and extinction coefficient were 
calculated from the N-domain amino acid sequence (see Appendix Figure A1) using 
the tool ProtParam on the ExPASy web site (http://au.expasy.org/cgi-bin/protparam). 
Sample purity and integrity was confirmed by fractionation on 10% polyacrylamide 
gels using standard sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (see Appendix A4). Protein was stained with Coomassie (0.2% (w/v) 
Coomassie Blue; 7% (v/v) glacial acetic acid; 50% (v/v) ethanol) and visualised by 
de-staining  
(7% (v/v) glacial acetic acid; 25% (v/v) ethanol) for 90 min. De-staining solution was 
changed at least once. Samples were stored in 1 ml aliquots at -20 °C until used. 
 
2.2.4 Deglycosylation of purified N-domain protein 
Purified N-domain (1 mg/ml) in 50 mM potassium phosphate (0.2% SDS, 1% β-
mercaptoethanol) was denatured by boiling for 5 min and then cooled on ice. 
Deglycosylation was then carried out by the addition of PNGase-F (100 units/ml) and 
incubated at 37 °C overnight.  
 
2.2.5 In-gel protease digestion for mass spectrometry analysis 
Deglycosylated ACE N-domain was fractionated using 10% polyacrylamide gels as 

















Coomassie staining as described above. The N-domain band was excised, cut into  
1 mm3 gel slices and further de-stained in 200 mM NH4HCO3, 50% acetonitrile. Gel 
slices were dehydrated using a Speed vac®, before reduction with 5 mM 
triscarboxyethyl phosphine (TCEP) in 100 mM NH4HCO3 for 30 min at 56 °C. Excess 
TCEP was removed and the gel slices dehydrated. Cysteines were protected with 
the addition of 100 mM iodoacetamide in 100 mM NH4HCO3 and incubated at room 
temperature in the dark for 30 min. Gel slices were dehydrated and washed with 50 
mM NH4HCO3 and dehydrated again. Gel slices were rehydrated by the addition of 
20 ng/μl protease (trypsin or endoproteinase Glu-C) and digested at 37 °C overnight. 
Peptides were solubilised with 50 μl 0.1% trifluoroacetic acid (TFA). The peptides 
were lyophilised, rehydrated in 50 μl water, and concentrated to less than 20 μl in a 
Speed vac®, to remove residual NH4HCO3. 
 
2.2.6 Mass Spectrometry 
Mass spectra were recorded on an ABI 4800 matrix assisted laser desorption-
ionisation time of flight (MALDI-ToF/ToF) mass spectrometer (Applied Biosystems 
Foster City, CA, USA), using positive reflector mode. Spectra were generated with 
400 laser shots/spectrum, at an intensity of 3800 (arbitrary units), with a grid voltage 
of 16 kV. All peptide containing spots were internally calibrated using trypsin autolytic 
fragments. The matrix used was α-cyano-4-hydroxycinnamic acid, at a final 
concentration of 5mg/ml matrix in 40% acetonitrile, 0.1% TFA, 10 mM NH4H2PO4 
(Fluka, Buchs, Switzerland). 
 
2.3 Results 
To identify which of the N-linked sites on the N-domain were glycosylated, WT  
N-domain was deglycosylated with PNGase-F, which removes the entire glycan from 
the Asn attachment site. Complete deglycosylation of purified N-domain was 
confirmed by SDS-PAGE, where an increased electrophoretic mobility relative to 




















Figure 2.1: PAGE gel showing purity of N-domain protein and increased 
electrophoretic mobility after enzymatic deglycosylation. Lane 1 - Biorad Precision plus 
protein™ standard, Lane 2 - untreated purified N-domain. Lane 3 - PNGase-F treated N-
domain. Additional bands indicated by arrows. 
 
A diffuse band was noted for the PNGase treated sample, as well as a few additional 
bands. This may have been the result of proteolysis (lower bands) or partial 
deglycosylation (upper bands). However, this did not affect the analysis, as the 
protein band of interest was specifically excised. Disulfide bridges were reduced and 
alkylated in the excised gel fragments to prevent disulfide bond formation, which 
would confound the mass spectrometry data by linking cleaved peptides together. 
Following cysteine protection, the excised band was subjected to in-gel digestion 
with either trypsin or Glu-C and the resulting peptides analysed my MALDI-ToF/ToF 
mass spectrometry. 
 
Mass spectrometry analysis of PNGase-F treated N-domain peptides resulting from 
tryptic and Glu-C digestion successfully revealed a number of N-domain peptides. 
Mass spectrometry of the tryptic peptides resulted in a sequence coverage of about 
75%, while analysis of the spectra produced from Glu-C peptides revealed another 

















N-domain were covered by this approach (Table 2.2). Importantly, all of the potential 




Table 2.2: Tryptic and Glu-C peptides of PNGase-F treated N-domain showing 
calculated and observed MH+ ions. Singly charged ions are indicated. Peptides containing 
potential glycosylation sites are highlighted in bold. PNGase-F deamidates the Asn (114 Da) 
residue of the glycosylation sequon to an Asp (115 Da). This increase of 1 Da can be used 
to identify the presence of N-glycosylation at potential glycosylation sites. 
 
2.3.1 Glycosylation sites identified from deglycosylated tryptic peptides of the 
N-domain  
As mentioned above, various peptides containing potential glycosylation sites were 
detected. The majority of these were peptides resulting from tryptic digestion of the 



















Figure 2.2: Representative MALDI-ToF/ToF spectrum of tryptic peptides from PNGase-
F digested ACE N-domain. Masses indicate singly charged ions. Peptides resulting from 
tryptic digestion of the N-domain are labeled. Glycopeptides containing sites 4 (m/z 2050.00), 
5 (m/z 1425.69), 8 (m/z 1625.79), 9 (m/z 1090.50) and 10 (m/z m/z 1342.74) are indicated 
by arrows. 
 
Observed molecular ions from the tryptic digest at m/z 2050.00, 1425.69, 1625.79 
and 1090.50 (Figure 2.2), were 1 Da greater than the calculated masses of [MH]+ 
2049.00 (Glu74-Arg89), 1424.69 (Gln109-Arg120), 1624.80 (Val414-Lys427) and 1089.49 
(Asp480- Lys489), consistent with PNGase-F deamidation of Asn at sites 4 (N82),  
5 (N117), 8 (N416) and 9 (N480), respectively. The observed ion at m/z 1342.76 
agrees well with the expected mass of [MH]+ 1342.72 for Phe490-Arg500 indicating 

















peptides were fragmented by MS/MS (Figure 2.3), where the Asn to Asp 
deamidation was confirmed in each case. The exception, of course, was site 10 





Figure 2.3: Representative MALDI-ToF/ToF-MS/MS spectra for the sequencing of 
potential glycopeptides. The sequence of the fragmented glycopeptide m/z 1625.79, 
containing glycosylation site 8 (N416) is indicated. The “y” and “b”-ion series are shown. The 
asterisk indicates a deamidated Asn (N416), causing a mass increase of 1Da. 
 
An observed mass at m/z 1394.61 corresponds well with the expected mass of 
1393.51 for (Ile127- Lys 132) given the presence of glycosylation at site 6 (N131), while 
the remaining site, site 7 (N289), was detected at m/z 2448.20 which corresponds 
well with the calculated mass of 2448.14 (Pro246-Arg295), assuming glycosylation at 
site seven (N289) and tryptic cleavage after Lys274, which is followed by a Pro. While 
it is typically thought that trypsin does not cleave after a Lys or Arg when the residue 

















cleaved 145. The likelihood of such cleavage is increased when the protein is 
exposed to extended overnight digestion, as was the case here. MS/MS sequencing 
of these two peptides was hampered by the fact that they could not be fragmented. 
 
2.3.2 Glycosylation sites identified from deglycosylated Glu-C peptides of the 
N-domain 
While analysis of the mass spectrometry data resulting from tryptic digestion of the 
N-domain enabled the identification of the glycosylation site occupancy of seven of 
the potential glycosylation sites. The glycosylation status of sites 1 (N9), 2 (N25) and 
3 (N45) could not be determined, as these sites all occur on a single large tryptic 
peptide. Further analysis of the amino acid sequence of this region revealed four 
Glu-C cleavage sites. Fortuitously, these cleavage sites were such that glycosylation 
sequons 1, 2 and 3 all occur on separate Glu-C peptides, the sizes of which were 
between 1000 and 3000 Da, making them ideal candidates for identification by mass 
spectrometry. Mass spectra of peptides resulting from Glu-C digestion of PNGase-F 
treated N-domain showed a peak at m/z 1460.56 which corresponds closely with the 
calculated masses of [MH]+ 1459.65 for the peptide Leu1-Glu14, assuming site 1 (N9) 
was glycosylated and the Asn converted to Asp by PNGase-F. Similarly, observed 
peaks at m/z 1544.60 and 2188.92 agree with calculated masses of [MH]+ 1543.68 
and 2188.04 for peptides Ala15-Glu29 and Gln30-Glu49, assuming glycosylation at sites 
2 (N25) and 3 (N45), respectively. The sequence of these peptides were further 
confirmed by MS/MS fragmentation of the relevant parent ions and showed 
deamidation of the Asn to Asp by PNGase-F in each case (Figure 2.4), confirming 






















Figure 2.4: Representative MALDI-ToF/ToF-MS/MS spectra for the sequencing of 
potential glycopeptides. The sequence of the fragmented glycopeptide m/z 1544.60, 
containing site 2 (N25), is indicated. The “y” and “b”-ion series are shown. The asterisk 
indicates a deamidated Asn (N25), causing a mass increase of 1Da. 
 
2.4 Discussion 
Protein glycosylation plays a major role in regulating protein folding and function and 
is one of the most important post-translational modifications to occur in the 
endoplasmic reticulum and golgi systems of eukaryotic organisms 68. Determining 
the glycosylation site occupancy is an important step toward understanding the 
relative importance of the various glycosylation sites on a protein, as glycosylation of 
specific sites is often crucial for the folding and function of glycoproteins 146. In this 
regard, mass spectrometry combined with enzymatic deglycosylation and 
endoproteinase digestion has proven to be a useful tool in identifying the presence of 
attached glycans 146,147. Indeed this approach was used to identify glycan containing 
sequons for another carboxypeptidase, (glutamate carboxypeptidase II) which also 

















enzymatic deglycosylation and endoproteinase digestion revealed that all of the ten 
sequons contained carbohydrates. 
 
While sACE has 17 potential N-linked glycosylation sequons, it is estimated that only 
between seven and eight of these actually contain glycans. These findings are based 
on the mass difference between fully glycosylated and enzymatically deglycosylated 
sACE and the average size of a typical complex glycan chain 84. Furthermore, work 
carried out by Yu et al. (1997) on somatic ACE purified from human kidney cells, 
showed that glycosylation was present at sites 1 (N9), 2 (N25), 4 (N82), 5 (N117) 
and 9 (N480) of the N-domain. While it is likely that Yu et al. were able to identify 
most of the glycans present on sACE, it is possible that not all of the glycosylated 
sequons were identified as the authors were not able to identify all of the 
glycosylation sequon containing peptides. In addition, the glycosylation site 
occupancy of the N-domain of sACE is not necessarily the same as that of an 
individually expressed recombinant N-domain molecul , as was found to be the case 
for the C-domain 124. Interestingly, the crystal structure of the recombinant N-domain 
(expressed in the presence of NB-DNJ) shows ordered density for GlcNac residues 
at sites 2 (N25), 5 (N117) and 9 (N480) 139. 
 
Our approach of using mass spectrometry and enzymatic deglycosylation combined 
with endoproteinase digestion was able to achieve up to 90% sequence coverage for 
the N-domain, and has allowed for the profiling of all ten of the potential  
N-glycosylation sites. Additionally, a number of non-glycopeptides were identified 




















Table 2.3: Observed molecular ions for potential glycopeptides from tryptic and 
endoproteinase Glu-C digests of PNGase-F treated ACE N-domain. Singly charged ions 
are indicated. PNGase-F deamidates the Asn (114 Da) residue of the glycosylation sequon 
to an Asp (115 Da). This increase of 1 Da can be used to identify the presence of  
N-glycosylation at potential glycosylation sites. * Refers to calculated mass if the peptide 
was not glycosylated and therefore not deamidated by PNGase-F. 
 
Here we report that nine of the ten potential glycosylation sites on the N-domain 
contain glycans when expressed from CHO cells, with only site 10 (N494) being 
found to be unglycosylated (Table 2.3). Site 10 was not expected to be glycosylated 
since this site is located in the interior of the protein close to the active site and 
additionally, the glycosylation sequon is followed by a Pro residue which is known to 
interfere with oligosaccharidal transferase recognition of the glycosylation sequon 56. 
For these reasons, this site was also predicted by NetNGlyc to be unglycosylated 
(Table 2.1).  
 
Thus, recombinantly expressed N-domain has a high degree of glycosylation site 
occupancy (90%); much greater than that of the C-domain which has only three out 
of seven potential glycan sites in the glycosylated form, although an additional three 
sites have been found in both glycosylated and unglycosylated forms 124. The 
identification that the three N-terminal sites on the C-domain were always 

















C-terminal sites that were found in both glycosylated and unglycosylated forms. This 
fact was born out in mutagenic studies involving the removal of a number of 
glycosylation sites from the C-domain, where it was found that the three N-terminal 
sites were crucial for expression of active protein, while removal the other three had 
little effect on the expression of the C-domain 122. Our findings, however, did not 
highlight particular glycosylation sites which may be important for the processing, 
folding or thermal stability of the N-domain, since virtually all sites were found to be 
glycosylated. However, the fact that site 10 is not glycosylated allowed us to exclude 
this site from further experiments aimed at identifying which glycosylation sites are 


























To determine the role of the various N-glycosylation sites with respect to the 
expression of functional protein and thermal stability, a number of N-domain mutants 




Figure 3.1: Schematic diagram of glycosylation mutants generated by P. 
Redelinghuys (2006), with the activity status of each mutant indicated. Black boxes 
indicate intact N-glycosylation sequons and white boxes show sites that are not glycosylated. 
Ndom stands for N-domain, while the numbers indicate the intact glycosylation sites.  
 
Previous work focused on the removal of C-terminal glycosylation sites from the  
N-domain, based on the fact that the N- and C-domains share a high degree of 
sequence and structural homology and the finding that N-terminal sites were 

















showed that C-terminal rather than N-terminal sites were important for the 
expression of N-domain proteins. While the presence of only one or two N-terminal 
sites was sufficient for expression of C-domain proteins, the removal of three  
C-terminal sites from the N-domain resulted in the expression of inactive protein 
(Figure 3.1).  
 
Thus, a series of mutants were generated to assess the importance of the C-terminal 
glycosylation sites of the N-domain. A specific requirement for C-terminal sites, 
however, does not preclude a role for N-terminal sites in the processes of thermal 
stability and expression of functional protein. Therefore, a series of mutants were 
generated to investigate the importance of these sites in the expression of functional 
N-domain proteins. While C-terminal sites are important, the most C-terminal site, 
site ten (Asn 480) was shown to be unglycosylated (see Chapter 2.4), thus, it was 
not deemed necessary to investigate the importance of this site and consequently, it 




1. To reintroduce various C-terminal sites into an existing construct to determine 
whether C-terminal sites rather than N-terminal sites are required. 
2. To selectively remove various N-terminal sites to determine whether they 
affect enzyme processing and thermal stability. 
3. To generate glycosylation mutants with three or fewer intact glycosylation 
sites to determine the minimum glycosylation requirements for the N-domain 



















3.2 Experimental procedures 
3.2.1 Materials 
O’generuler DNA Ladder mix, restriction endonucleases EcoRI, Hind III, Eco47III, 
Eco91I, BglII, BsmI, PvuI, NotI and XbaI as well as T4 DNA ligase were purchased 
from Fermentas (Ontario, Canada). E.coli DH5α cells, Dpn I and the Wizard® SV gel 
and clean-up kit were obtained from Promega. MluI, BalI and RcaI were obtained 
from Roche.  
 
3.2.2 N-domain plasmid templates  
Site-directed mutagenesis of the glycosylation sequons was carried out on three 
previously generated human N-domain glycosylation mutants, namely Ndom123456 
Ndom123 and Ndom0, where “Ndom” stands for N-domain and numerals indicate 
intact glycosylation sites 125. Mutagenic products were used as templates for further 
mutagenesis in an iterative cycle. 
 
3.2.3 Mutagenic oligonucleotides 
Primers were designed using Watcut (Michael Palmer, University of Waterloo, 
Canada. http://watcut.uwaterloo.ca/watcut) and were synthesised by Inqaba biotech 
South Africa. Primers were engineered to introduce an Asn to Gln codon change in 
the Asn-Xaa-Ser/Thr recognition sequon (or to reverse such a change from a 
previously mutated sequon). Additionally, restriction sites were either introduced or 
removed via the introduction of silent mutations, to enable screening of positive 




















Table 3.1: Mutagenic oligonucleotides for the disruption or restoration of 
glycosylation sequons. Introduced, or removed (*) restriction sites are underlined and 
codon changes are indicated in bold lowercase. Forward (F) and reverse (R) primers shown. 
 
3.2.4 Site-directed mutagenesis and cloning of glycosylation mutants 
3.2.4.1 Site-directed mutagene is 
A modified version of the Quickchange™ (Stratagene, CA, USA) DpnI method of site-
directed mutagenesis 149 was used to disrupt, or repair, glycosylation sequons in the 
N-domain. Reactions were carried out in a Hybaid PCRSprint thermocycler (Mandel 
Scientific Company Inc, Ontario, Canada) using the Kapa Hifi PCR kit (Kapa 
Biosystems, Cape Town, South Africa) according to the manufacturer’s instructions. 
Briefly, 10 ng of the relevant template DNA was used in each 50 µl PCR reaction. 
The cycling parameters consisted of one cycle of 95 °C for 2 min, then 20 cycles of 
95 °C for 0.3 min, X °C for 0.5 min (where X = Tm of the primer-target complex), 
68 °C for 3 min, followed by a final extension cycle of 5 min at 68 °C. Primer-target 
Tm values were calculated using a the following equation: Tm = 81.5 + 0.41(% GC) - 
675/N -% mismatch, where N = total number of bases. Thermal cycling was carried 
out with the relevant mutagenic primers. Successful mutagenesis was confirmed by 

















0.09 M Boric acid, 2.0 mM EDTA, pH 8.0, 0.3 µg/ml ethidium bromide). Following 
confirmation of successful mutagenesis, methylated and hemi-methylated template 
DNA was removed by DpnI digestion (Figure 3.2 A) and transformed into competent 




Figure 3.2: Schematic of the Dpn I method of site-directed mutagenesis (A) and the 
subcloning strategy (B). The EcoRI and XbaI restriction sites used for subcloning are 
indicated. 
 
3.2.4.2 Crude isolation of plasmid DNA for screening of positive clones  
Colonies were picked into 3 ml Luria broth (LB) containing 50 µl/ml ampicillin and 
incubated overnight at 37 C with shaking. Plasmid DNA was isolated using the 
STET boiling-lysis method 150. Overnight culture (1 ml) was transferred to an 
eppendorf tube and centrifuged for 2 min at 12000 rpm. The cell pellet was  
re-suspended in 250 l of STET buffer (8% (w/v) sucrose; 5% (w/v) triton X-100; 50 
mM EDTA; 50 mM TRIS, pH 8.0) containing 1 mg/ml lysozyme. Suspensions were 

















toothpick and discarded. Isopropanol (0.25 volumes) was added to the remaining 
supernatant and mixed by inversion. Following addition of isopropanol, samples 
were centrifuged for 8 min to pellet the DNA. The supernatant was removed and the 
plasmid DNA pellet was air-dried. Finally, the DNA pellet was re-suspended in 1/10x 
tris-EDTA (1.0 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and heated to 68 C for 10 min 
to ensure solubilisation of the DNA. Each DNA preparation was subjected to 
restriction enzyme (RE) digestion (see Appendix A3), to determine the presence of 
the introduced restriction site. Digest products were visualised on 1% (w/v) agarose 
gels. 
 
3.2.4.3 Small scale preparation of plasmid DNA for sequencing and sub-
cloning 
Positive clones, identified by restriction enzyme digest screens, were picked into 2 
ml LB containing 50 µg/ml ampicillin, and incubated overnight at 37 ˚C with shaking.  
Plasmid DNA isolation was carried out using the Zippy plasmid miniprep kit (Zymo 
research, USA) as per the manufacturer’s instructions. The DNA pellet was  
re-suspended in 20 µl nuclease free H2O (NF H2O), and the concentration calculated 
from the absorbance at 260nm, using a Nanodrop® ND1000 (NanoDrop 
Technologies, Wilmington, USA). Successful mutagenesis was further confirmed by 
automated DNA sequencing carried out by Macrogen Inc. (Seoul, Korea). 
Sequencing primers shown in Appendix Figure A2. 
 
3.2.4.3 Sub-cloning of N-domain constructs for mammalian transfection 
Glycosylation mutant N-domain inserts were subcloned from the pBSKII cloning 
vector into the mammalian expression vector pCDNA3.1+ (Invitrogen, CA, USA), 
using the EcoRI and XbaI restriction sites (Figure 3.2 B). Glycosylation mutants in 
pBSKII, as well as the expression vector pcDNA3.1+, were digested with EcoRI and 
XbaI and DNA fragments separated by agarose gel electrophoresis. Relevant DNA 
fragments were excised using the Wizard® SV gel and clean-up kit (Promega) 
according to the manufacturer’s instructions, resuspended in 50 µl NF H2O and DNA 
concentrations were quantified using a Nanodrop® ND1000 as mentioned above. 
Ligations were carried out overnight at room temperature (RT), or over three days at 

















buffer (Fermentas, Burlington, Canada), X µl insert DNA, 3X µl pCDNA 3.1+, 1.5 U 
T4 ligase (Fermentas Burlington, Canada), made up to 20 µl with N.F. H2O 
Competent DH5α cells were transformed with 10 µl ligation mixture. DNA from 
resistant clones was prepared using the STET method above. Prepared DNA was 
screened for the presence of the relevant restriction endonuclease sites as 
mentioned above. 
 
3.2.4.4 Scaled up preparation of plasmid DNA for transfection 
A 100 µl aliquot of bacterial culture, identified as positive for the desired mutation by 
the restriction digest screen, was inoculated into 50 ml LB containing 50 µg/ml 
ampicillin, and incubated overnight at 37 ˚C with shaking. Bulk plasmid DNA isolation 
was carried out using the Qiagen Midi-preparation kit (GmBH, Hilden, Germany), as 
per the manufacturer’s instructions. The DNA pellet was re-suspended in 100 µl  
NF H2O, and the concentration calculated from the absorbance at 260nm, using a 
Nanodrop® ND1000. Isolated DNA was screened for the presence of the relevant 
restriction endonuclease site introduced during mutagenesis, as mentioned above. 
 
3.3 Results 
Previous work has highlighted the role of C-terminal glycosylation sites in the 
expression of active N-domain proteins 125. That study produced a number of  
N-domain glycosylation mutants (Figure 3.1), most of which were inactive due to the 
fact that glycosylation sites were sequentially removed from the C-terminus 
(glycosylation of the C-terminus was subsequently found to be important for the 
expression of active N-domain). Rather than investigate the importance of the  
C-terminal glycan sites by sequentially removing the N-linked sequons from the  
N-terminus, it seemed more efficient to make use of the previously generated 
glycosylation mutants, using these as templates for reintroducing the C-terminal 
glycan sites via site-directed mutagenesis. Primarily making use of the previously 
generated N-domain glycosylation variants Ndom123456, Ndom123 and Ndom0 
(which has no intact N-linked glycosylation sites), a range of additional N-domain 



















Figure 3.3: Schematic repr sentation of constructed glycosylation mutants. Black 
boxes indicate intact glycosylation sequons, Grey boxes show reintroduced sequons, Grey 
crosses indicate removed sequons. Site 10 (white box) is not glycosylated. “*” indicates 
previously generated mutants 125 used as templates. Mutants are grouped according to the 
template they were constructed from. 
 
Previous mutagenic studies have shown that Ndom1234567 is expressed as an 
active protein, while Ndom123456 is not. These data suggesting that site 7 is 
important for the expression of active N-domain protein. In order to assess whether 
other C-terminal sites were important, we decided to reintroduce site 9 into the  
N-domain variant Ndom123456, to see whether the presence of site 9 could rescue 
the inactive mutant. Thus, site 9 was introduced into Ndom123456 to create 
Ndom1234569 (as in Figures 3.1 and 3.3, the numbers indicate the intact  
N-glycosylation sites), in the process, the MluI restriction site at position 2491 was 

















loss of 5.1 and 1.5 kb DNA fragments and the formation of a 6.7 kb fragment is 
evidence of the removal of the MluI site and thus incorporation of the desired Glu to 




Figure 3.4: Vector map and restriction endonuclease digest of Ndom1234569, 
generated from Ndom123456. Digested with MluI and EcoRI. The RE site MluI (2491) is 
removed during mutagenesis. Lane 1 - O’generuler DNA ladder mix, Lane 2 - Ndom1234569, 


























Given the suggested importance of the C-terminal site 7, it was decided to introduce 
this site into the hypoglycosylated N-domain variant Ndom123 to generate 
Ndom1237, and assess whether the presence of site 7 could rescue activity for this 
variant. An additional BsmI site at position 1929 was incorporated during 
mutagenesis. Given that there were two existing BsmI sites present in the template, 
digestion with BsmI alone was sufficient to identify positive clones. The loss of a 
DNA fragment at 3.9 kb and the formation fragments at 3.2 and 0.7 kb, after BsmI 




Figure 3.5: Vector map and restriction endonuclease digest of Ndom1237, generated 
from Ndom123. Digested with BsmI. The RE site BsmI (1929) is introduced during 






















In the event that site 7 alone is not sufficient to rescue activity for the Ndom1237 
mutant, it was decided to introduce site 9 into Ndom1237. In this way Ndom12379 
was generated. An MluI restriction enzyme site, at position 2491, was removed 
during mutagenesis, thus the loss 5.1 and 1.5 kb DNA fragments and the formation 
of a 6.7 kb fragment, after digestion with MluI and EcoRI, indicates successful 




Figure 3.6: Vector map and restriction endonuclease digest of Ndom12379, generated 
from Ndom1237. Digested with MluI. The RE site MluI (2491) is removed during 

























To ensure that all of the C-terminal sites were investigated, site 8 was introduced 
into Ndom12379 to generate Ndom123789. A PvuI site at position 2295 was 
removed during mutagenesis. An additional PvuI site is present in the template DNA, 
thus removal of the site at position 2295 results in the loss of a fragments at 4.5 and 
2.8 kb and the formation of a new fragment of 7.3 kb, consistent with linearisation of 




Figure 3.7: Vector map and restriction endonuclease digest of Ndom123789, 
generated from Ndom12379. Digested with PvuI. The RE site PvuI (2295) is removed 
during mutagenesis. Lane 1 - O’generuler DNA ladder mix, Lane 2 - Ndom123789, Lane 3 - 
Ndom12379. 
 
While C-terminal sites were previously shown to be important for the expression of 
N-domain protein, the importance of the N-terminal sites (or the lack thereof) cannot 
be taken for granted. Thus, the three N-terminal sites were removed from 
Ndom12379 individually, to assess their relative importance for the expression of 


















Site 1 was removed from Ndom12379 to create Ndom2379, where a BalI site at 
position 1082 was introduced during mutagenesis. Thus, digestion with XbaI and 
BalI results in the loss of a fragment at 6 kb and the formation of fragments at 4.2 




Figure 3.8: Vector map and restriction endonuclease digest of Ndom2379, generated 
from Ndom12379. Digested with XbaI and BalI. The highlighted RE site BalI (1082) is 
introduced during mutagenesis. Lane 1 - O’generuler DNA ladder mix, Lane 2 - Ndom2379, 


























Site 2 was removed from Ndom12379 to create Ndom1379. An Eco47III site at 
position 1140 was introduced for the screening of positive clones. Digestion with 
XbaI and Eco47III results in the loss of a fragment at 7.4 kb and the formation of 




Figure 3.9: Vector map and restriction endonuclease digest of Ndom1379, generated 
from Ndom12379. Digested with XbaI and Eco47III. The highlighted RE site Eco47III (1140) 
is introduced during mutagenesis. Lane 1 - O’generuler DNA ladder mix, Lane 2 - 


























Site 3 was removed from Ndom12379 (N45Q) to generate Ndom1279. An additional 
RcaI site at position 1182 was introduced during mutagenesis. Given that there were 
two existing RcaI sites present in the template, digestion with RcaI alone was 
sufficient to identify positive clones. The loss of DNA fragments at 6.4 kb and the 
formation fragments at 5.1 and 1.3 kb, after RcaI digestion, represents successful 




Figure 3.10: Vector map and restriction endonuclease digest of Ndom1279, generated 
from Ndom12379. Digested with RcaI. The highlighted RE site RcaI (1182) is introduced 
during mutagenesis. Lane 1 - O’generuler DNA ladder mix, Lane 2 - Ndom1279, Lane 3 - 
Ndom12379. 
 
To generate a minimally glycosylated N-domain variant, we made used of an  
N-domain construct with all glycosylation sites removed (Ndom0). Ndom0 was thus 
used as a template for the reintroduction of various glycosylation sites, including 




















Thus, site 9 was introduced into Ndom0 to create Ndom9. As in the case of 
Ndom1234569 and Ndom12379 above, the loss of 5.1 and 1.5 kb DNA fragments 
and the formation of a 6.7 kb fragment, after digestion with MluI and EcoRI, indicates 




Figure 3.11: Vector map and restriction endonuclease digest of Ndom9, generated 
from Ndom0. Digested with EcoRI and MluI. The highlighted RE site MluI (2491) is removed 



























Site 7 was introduced into Ndom9 to generate Ndom79. As for Ndom1237 the loss of 
a DNA fragment at 3.9 kb and the formation fragments at 3.2 and 0.7 kb, after 





Figure 3.12: Vector map and restriction endonuclease digest of Ndom79, generated 
from Ndom9. Digested with BsmI. The highlighted RE site BsmI (1929) is introduced during 

























Site 8 was introduced into Nom79 (Q416N) to generate Ndom789. As for 
Ndom123789, the removal of the PvuI site results in the loss of a fragments at 4.5 




Figure 3.13: Vector map and restriction endonuclease digest of Ndom789, generated 
from Ndom79. Digested with PvuI. The RE site PvuI (2295) is removed during mutagenesis. 


























Similarly, site 8 was introduced into Nom9 (Q416N) to generate Ndom89. As in the 
case of Ndom123789 and NDom789 above, the removal of the PvuI site results in 
the loss of a fragments at 4.5 and 2.8 kb and the formation of a new fragment of 7.4 




Figure 3.14: Vector map and restriction endonuclease digest of Ndom89, generated 
from Ndom9. Digested with PvuI. The RE site PvuI (2295) is removed during mutagenesis. 
1-O’generuler DNA ladder mix, 2-Ndom89, 3-Ndom9. 
 
To assess whether an N-terminal site may be important for the expression of a 
minimally glycosylated N-domain form, Ndom389 was constructed. The construction 
of Ndom389 involved subcloning the N-terminal portion of a mutant containing only 
site 3 at the N-terminus. The previously generated mutant Ndom3 could 
unfortunately not be used for this purpose as it was found to contain a spurious 
coding mutation, W40L. Thus, Ndom379 was prepared by removing site 1 from 
Ndom1379 (as per the generation of Ndom2379 above). The N-terminal fragment of 
Ndom379 was then subcloned into Ndom89 using the RE sites BglII and EcoRI 



















Figure 3.15: Cloning strategy for the generation of Ndom389, from Ndom379 and 
Ndom89. Relevant RE sites are indicated, black dots represent intact glycosylation sites. 
 
Since Ndom89 had site 3 removed during earlier mutagenesis, the RcaI restriction 
site at position 1182 is present. Ndom379 however, does not have this site. Thus, 
successful subcloning of site 3 into Ndom89 could be confirmed by the absence of 
this RcaI site. Positive clones were therefore identified by digestion with RcaI, where 
the loss of 5.1 and 1.3 kb DNA fragments and the formation of a 6.4 kb fragment is 
evidence of the absence of the relevant RcaI site and thus the presence of an intact 

























Figure 3.16: Vector map and restriction endonuclease digest of Ndom389, generated 
from Ndom89 and Ndom1379. Digested with RcaI. The highlighted RE site RcaI (1182) is 
eliminated from Ndom89 during subcloning. Lane 1 - O’generuler DNA ladder mix, Lane 2 - 
Ndom389, Lane 3 - Ndom89. 
 
3.4 Discussion 
The aim of this work was to produce a series of N-domain forms with differing levels 
of intact glycosylation sites. The elimination of a glycosylation site can be achieved 
by the introduction of a conservative Asn to Gln substitution at the Asn of the Asn-
Xaa-Ser/Thr glycosylation consensus sequence. While there are many approaches 
to site-directed mutagenesis, three polymerase chain reaction (PCR) based 
approaches are most commonly used, namely overlap extension, megaprimer and 
modified forms of the Quickchange™ method 151. Both the megaprimer and overlap 
extension methods require two rounds of PCR 152,153. The Quickchange™ method, 
and its modified forms, require only a single PCR reaction 149,154. In our approach, 
the newly generated mutant was used as a template for subsequent mutagenesis of 
the glycosylation sites in an iterative cycle. Thus, the single step method of the 

















multiple mutant constructs. Therefore it was decided that this method was best 
suited for our study. 
 
In the case of the C-domain, the rationale for which sites were to be mutated was 
guided by previous work which showed that the three N-terminal sites of the  
C-domain were always glycosylated, while the following three sites were 
glycosylated with only partial efficiency 124. These findings suggested a preference 
for N-terminal glycosylation, which was later confirmed by mutagenesis of the 
glycosylation sites 122. Profiling of the glycosylation site occupancy of the N-domain 
did not reveal a similar pattern, with all of the sites containing glycosylation, 
excepting site 10 (see Chapter 2.3). Thus, no inferences could be made as to the 
relative importance of the different N-linked glycosylation sites on the N-domain, 




Figure 3.17: Surface representation of the N-domain of ACE, showing the location of 
the different N-linked glycosylation sites (orange). N- and C-termini are labelled in blue 
and red respectively. Glycosylation sites are numbered. Figure was drawn with PyMOL 
v0.92 using the PDB structure 2C6N 139 (DeLano Scientific, San Carlos, CA, USA). 
 
Analysis of the N-domain crystal structure showed that the different N-linked sites 

















N-terminal sites 1 to 4 were found to be located on the lid helices, which are thought 
to play an important role in the proposed hinge movement (discussed further in 
Chapter 4.4.2). Therefore, initial attempts to generate glycosylation mutants of the  
N-domain were carried out as per the C-domain approach, with the sequential 
removal of glycan sites from the C-terminus 125. Results from that initial study 
revealed that, contrary to what was seen in the C-domain, the C-terminal sites were 
important for the expression of active N-domain protein. Given these findings, the 
primary focus of our study was to generate a range of hypoglycosylated mutants 
containing various degrees of glycosylation at the C-terminus. In addition, a number 
of mutants with reduced N-terminal glycosylation were generated to assess the 
relative contribution of these sites on the expression and thermal stability of the  
N-domain. 
 
In total 13 mutants were successfully generated (Figure 3.3), of which 11 were 
subsequently used for further investigation, while two constructs, Ndom9 and 
Ndom379, were used as intermediates in the generation of the different glycosylation 
mutants, and were not expressed in CHO cells. The various hypoglycosylated 
mutants can be grouped into three categories, namely: mutants aimed at 
establishing the role of C-terminal sites (Ndom1234569, Ndom1237, Ndom12379 
and Ndom123789); mutants designed to evaluate the role of N-terminal sites 
(Ndom2379, Ndom1379 and Ndom1279) and mutants designed to produce 


























Protein N-glycosylation is known to affect a number of properties, including protein 
folding, processing and thermal stability 50,67,155. The expression of functional ACE 
protein requires the presence of N-glycosylation. This is evidenced by the fact that 
ACE isoforms expressed in bacterial systems which lack glycosylation machinery, 
and ACE expressed in the presence of tunicamycin, which blocks all N-linked 
glycosylation, are inactive and rapidly degraded 112. It has been determined that only 
one or two of the N-terminal glycosylation sites are required for the expression of 
functional C-domain 122. The glycosylation requirements for the expression of the  
N-domain have not been determined, although it is known that C-terminal 
glycosylation is important 125. 
 
Glycosylation was found to play a significant role in conferring thermal stability to the 
C-domain of ACE, where a series of glycosylation mutants showed that decreasing 
levels of glycosylation correlated with a decrease in thermal stability 136. While 
glycosylation of the N-domain is known to affect its stability 136, little is known about 
the glycan sites involved and the extent to which glycosylation affects thermal 
stability. However, previous work has shown that the N-domain is significantly more 
thermostable than the C-domain, with a Tm of 72 °C, as compared with 55 °C for the 
C-domain 104,136.  
 
There are various methods for assessing the level of protein thermal stability, 
including quantitative approaches such as differential scanning calorimetry (DSC), 
circular dichroism (CD), and the more qualitative assessment of residual activity 
following various lengths of exposure to thermal denaturation. CD spectroscopy is 
particularly useful in that it reveals signature profiles for protein secondary structures 
such as α-helix, β-sheet and random coil (unfolded) (Figure 4.1). Thus, performing 

















transition from high α-helical content, for example, to an unfolded state (random coil). 
Plotting this change in ellipticity as a function of temperature allows one to calculate 




Figure 4.1: Theoretical CD spectra for all α-helix, all β-sheet or all random coil 




1. To determine the role of different N-linked glycosylation sites in the 
expression of N-domain proteins. 
2. To determine the minimum glycosylation requirements of the expression of 
functional N-domain proteins. 
3. To assess the effect of reduced glycosylation on the enzyme kinetics of the  
N-domain. 
4. To determine the effect of glycosylation on the thermal stability of the  



















4.2 Experimental procedures 
4.2.1 Transfection, expression and purification of N-domain glycosylation 
variants 
Transfection, expression and purification of N-domain glycosylation variants was 
carried out as described in Chapter 2.2.2 and 2.2.3.  
 
4.2.2 Enzymatic activity assay and Western blotting 
ACE activity was assayed using the substrate Z-Phe-His-Leu (Z-FHL) (Bachem, 
Budendorf, Switzerland) (see Appendix A6). Protein concentrations were determined 
as described in Chapter 2.2.3. Three hundred nano grams of protein were 
fractionated by SDS-PAGE (see Appendix A4) and immunoblotting of purified 
recombinant ACE N-domain proteins was carried out as described in Appendix A5. 
Data were plotted using Graphpad Prism 4.01. 
 
4.2.3 Reverse-transcription PCR (RT PCR) 
Total RNA was isolated from CHO cells using Trizol Reagent (Invitrogen, CA, USA) 
according to the manufacturer’s instructions. RNA concentrations were determined 
by spectrophotometry at 260 nm. Reverse transcription of total mRNA was carried 
out using the Advantage RT-for-PCR kit (Clonetech, CA, USA), in a Hybaid PCR 
Sprint thermocycler (Mandel Scientific Company Inc, Ontario, Canada), according to 
the manufacturer’s instructions. Specific amplification of ACE N-domain cDNA was 
achieved using the forward and reverse primers 5'-TTTGCCTGGGAGGGCTGGCA-
3' and 5'-TGGTCCACCAAGTAGCCAAA-3' which correspond to nucleotides 581-600 
and 1421-1440, of the ACE N-domain sequence (Genbank accession number 
NM_000789.2). Ten micro litres of total cDNA product was used as a template in 
each 50 µl PCR reaction. The cycling parameters consisted of one cycle of 95 °C for 
2 min, then 20 cycles of 95 °C for 0.3 min, 58 °C for 0.5 min, 68 °C for 1.5 min 
followed by a final extension cycle of 3 min at 68 °C. PCR products were 
electrophoresed on 1% (w/v) agarose gels in TBE, using O’GeneRuler DNA ladder 


















4.2.4 Thermal denaturation assay 
Purified recombinant ACE proteins were incubated at 55 °C for up to 60 min in 50 
mM HEPES, pH 7.4. Residual activity was determined using the above mentioned 
ACE assay. 
 
4.2.5 Determination of melting temperatures (Tm) 
Far-UV CD spectra were recorded on a Jasco J-810 spectrometer (Jasco 
Corporation, Easton, USA). Ellipticity was monitored from 210 to 260 nm using a 
protein concentration of 0.04 mg/ml (in 100 mM phosphate buffer, pH 7.5). Ellipticity 
at lower wavelengths (190 - 210 nm) could not be measured due to instrument 
limitations, as a result of the high voltage required to scan these wavelengths under 
our conditions (see Chapter 4.4.3). Proteins were exposed to thermal denaturation in 
5 °C increments from 30 to 90 °C at a rate of 0.43 °C/min. Ellipticity was plotted as a 
function of temperature using Graphpad Prism 5.01 (Graphpad software, CA, USA). 
Melting points were obtained from the first derivative of the unfolding transition curve 
and are reported as mean values of five different sigmoidal fits. Previous work has 
shown that thermal inactivation of ACE is irreversible 104, therefore, this aspect was 
not investigated further. 
 
4.2.6 Determination of kinetic constants for the hydrolysis of Z-FHL 
Kinetic parameters for the hydrolysis of Z-FHL (Bachem, Budendorf, Switzerland) 
were determined using the standard ACE assay (see Appendix A6), except that 
initial reaction rates were calculated using Z-FHL concentrations ranging from  
0.00 to 2.54 mM. Assays were repeated at least three times in triplicate. Data fitting 
and Michaelis-Menten constants, Km, Vmax, kcat and kcat/Km, were determined using 
GraphPad Prism 5.01. Specific activities of samples at the time of assaying were 
compared to values obtained immediately after purification and the percent active 
protein calculated. Kinetic values were then normalised according to the percentage 



















4.3.1 The effect of different glycosylation profiles on the expression of active 
N-domain 
As shown in Chapter 3, a range of glycosylation mutants were generated  




Figure 4.2: Schematic diagram of the N-domain glycosylation mutants. Black boxes 
indicate intact glycosylation sites, while the white boxes indicate an unglycosylated site. 
 
WT N-domain and the various glycosylation mutants were expressed in CHO cells. 
As per Chapter 2.2.3, ACE N-domain proteins were purified from culture media and 
subjected to SDS-PAGE analysis, where the presence of a single prominent band 
and negligible degradation confirmed sample purity and integrity (Figure 4.3, 
Appendix Figure A3). Following purification, the effect of the differential glycosylation 
of these N-domain variants on protein expression, specific activity and thermal 




















Figure 4.3: Representative SDS-PAGE gels stained with Coomassie, showing 
successful purification of ACE N-domain protein. Lane 1 - Spectra™ broad range 
molecular marker. Lane 2 - Ndom1279. 
 
Previously Ndom123456 had been found to be inactive as a direct result of the 
removal of the three C-terminal glycosylation sites 125. The reintroduction of site 9 
into this mutant (Ndom1234569), however, was able to rescue activity (Figure 4.4A). 
Similarly, the hypoglycosylated mutant Ndom123 is also known to be inactive 125. 
However, it was found that activity could be rescued by the reintroduction of  
C-terminal sites 7, 8 and 9 (Ndom123789), 7 and 9 (Ndom12379) and, even site 7 
alone (Ndom1237) (Figure 4.4A). Removal of individual N-terminal glycosylation 
sites (site 1, 2 and 3) from the hypoglycosylated mutant Ndom12379 (creating 
Ndom2379, Ndom1379 and Ndom1279) had no major effect on the expression of 
active protein (Figure 4.4A). The hypoglycosylated variants Ndom79 and Ndom89 
were both found to be inactive. However, the reintroduction of either site 3 or site 7 
(Ndom389 and Ndom789) was able to rescue activity and produced functional 




















Figure 4.4: Expression of N-domain glycosylation variants. A) Specific activity of ACE 
N-domain and various glycosylation mutants are shown. B) Western blot of purified 
recombinant N-domain proteins, probed with an anti-N-domain antibody (4G6), Spectra™ 
broad range molecular marker indicates molecular sizes. 
 
In addition, Western blot analysis of the glycosylation mutants showed that an 
increase in electrophoretic mobility correlated with a decrease in the number of intact 
glycosylation sequons and thus N-glycan content of the proteins (Figure 4.4B). While 
an increase in electrophoretic mobility was noted, the increase was not directly 
proportional for all mutants, with Ndom1379 and Ndom1279 migrating slightly higher 

















been noted before and it is thought that the difference in molecular size/migration 
may be due to the presence of bulkier glycan groups at a particular site (or sites) 112, 




Figure 4.5: Agarose gel of RT-PCR products showing RNA isolation and mRNA 
transcription for inactive mutants. Lane 1 - O’generuler DNA ladder; Lane 2 - 
Ndom123456; Lane 3 - Ndom123; Lane 4 - Ndom79; Lane 5 - Ndom89; Lane 6 – 
untransfected CHO cells. Lane 7 - WT N-domain; Lane 8 - total RNA control. A) Agarose gel 
of total RNA isolated from transfected CHO cells, with 18S and 28S rRNA fragments 
indicated. B) Agarose gel showing specific amplification of N-domain mRNA. 
 
Inactive proteins Ndom123, Ndom123456, Ndom79 and Ndom89 could not be 
detected by Western blot. However, mRNA expression was detected by RT-PCR. 
Total RNA was isolated from CHO cells stably transfected with each of the inactive 
glycosylation mutants, as well as from WT N-domain and untransfected CHO cells 
as controls. RNA integrity was confirmed in each case by the presence of distinct 
fragments, corresponding to the S18 and S28 RNA sizes (Figure 4.5A). These 
fragments migrated to approximately 0.8 and 2.5 kb according to the double 
stranded DNA molecular ladder, which corresponds to the expected sizes of 1.8 and 
5 Kb, as RNA is single stranded. Messenger RNA was detected in each case by the 
specific amplification of a 0.8 kb fragment for the N-domain mutants, or a 1 kb 
fragment in the case of the control RNA sample (Figure 4.5B). These data indicate 

















intracellular degradation, a factor which is known to affect terminally misfolded 
membrane proteins in the ER, including underglycosylated and unglycosylated  
ACE 67,112. 
 
4.3.2 The effect of glycosylation on the thermal stability of the N-domain  
4.3.2.1 Thermal inactivation of N-domain glycosylation variants 
The thermal denaturation of the N-domain and its hypoglycosylated mutants was 
assessed following incubation at 55 °C, with the subsequent determination of 
residual activity using the ACE substrate Z-FHL. Wild type N-domain showed a 
remarkable level of thermal stability, retaining almost 80% of its activity after 30 min 
thermal inactivation at 55 °C, even after 60 min at 55 °C there was little change in 
enzyme activity (Figure 4.6). The removal of sites 4, 5 and 6 did not affect the 
thermal stability, with Ndom123789 retaining about 80% of its activity after 30 min. 
The removal of sites 7 and 8 (Ndom1234659), sites 4, 5, 6 and 8 (Ndom12379) and 
sites 4, 5, 6, 8 and 9 (Ndom1237) reduced the stability to between 70 and 55% after 
30 min. The removal of site 1 (Ndom2379), did not greatly alter the thermal stability 
from that of Ndom12379, with the variant retaining approximately 60% of its activity 
after 30 min at 55 °C. However, removal of either sites 2 or 3 from Ndom12379 (that 
is, Ndom1379 and Ndom1279) caused a remarkable loss of thermal stability, with 
just under 20% residual activity remaining after 10 min. These mutants were 
essentially inactive after 30 min of thermal denaturation. The hypoglycosylated 
mutant Ndom389 was even more unstable, with virtually no activity remaining after 
10 min thermal inactivation. Ndom789 was the most unstable of all the glycosylation 




















Figure 4.6: Thermal denaturation curve for ACE N-domain and glycosylation variants. 
Percentage residual activity was calculated using the standard ACE assay with Z-FHL as a 
substrate (see Chapter 4.2.2). Error bars indicate SE. 
 
4.3.2.1 Tm determination of N-domain glycosylation variants by CD 
spectroscopy 
Four N-domain glycosylation variants were selected for melting point (Tm) 
determination by CD spectroscopy, namely WT N-domain, Ndom2379, Ndom1279 
and Ndom389. These variants were selected such that glycosylation mutants with 
high, intermediate and low thermal stabilities were represented (based on the 
thermal denaturation studies above).  
 
The crystal structure of the N-domain of ACE reveals that the enzyme is comprised 
largely of α-helices 139. CD spectroscopy of α-helical proteins typically involves 
scanning the protein from 190 to 260 nm. This is because much of the change in 
ellipticity occurs over the 190 to 230 nm range (Figure 4.1) 156. However, we were 
only able to scan from 210 nm. This was due to the relationship between the voltage 
and the level of sample/buffer absorbance in the low ultra violet (UV) range. The 
voltage gives a direct measure of the amount of light being passed through the 
sample. Our sample and buffer preparation were moderately absorbent of circular 

















required amount of transmitted light. When the voltage exceeds 700 V, the CD 
output becomes unreliable due to a decrease in the signal to noise ratio 157. Since 
sample/buffer absorbance increases with decreasing wavelength, we were thus 
unable to scan ellipticity below 210 nm (Figure 4.7). Typically, a buffer dilution is able 
to resolve this issue 157. However, scans of buffer only revealed that the buffer was 
not responsible for the increased absorbance, indicating that the sample itself was 
the cause. Attempts to scan dilutions of the sample were not successful due to the 




Figure 4.7: Representative graph of voltage as a function of wavelength for a CD scan 
of WT N-domain. Voltage required for CD scans at 35 °C for WT N-domain and buffer. 
 
Despite the reduced range of wavelengths scanned, sufficient change in ellipticity 
was observed between 210 and 260 nm to allow calculation of Tm values. Initial 
circular dichroism scans of the different glycosylation variants at low temperature 
reported spectra typical of proteins with high α-helical content, as expected for the N-
domain. However, as the temperature was increased, a decrease in the level of 
ellipticity was noted, indicating a loss of α-helical content, typical of an unfolding 
transition  
(Figure 4.8). The WT N-domain protein began thermal transition at approximately 
55 °C and reached plateau at about 80 °C, while the same transition occurred 

















and Ndom389, however, underwent transition at a much lower temperature (40 °C) 




Figure 4.8: Circular dichroism spectra of N-domain variants showing temperature 
induced denaturation. Unfolding transitions for WT N-domain, Ndom2379, Ndom1279 and 
Ndom389 are shown over 210 to 260 nm. Scans for selected temperatures shown. 
 
The calculated Tm for WT N-domain was 60.3 °C (Figure 4.9), which is lower that the 
literature value for the N-domain (±70 °C), yet still higher than that of the C-domain 
(±52 °C) 104,136. Ndom2379 reported a Tm somewhat lower than that of WT N-domain 
(53.9 °C ±0.3), while Ndom1279 and Ndom389 had markedly lower values of 
45.9 °C ±0.1 and 42.7 °C ±0.2 respectively. As a control, the Tm for BSA fraction-V 
(Sigma) was determined (see Appendix Figure A4) and found to be ±67 °C, which 



















Figure 4.9: Thermal denaturation of N-domain glycosylation variants. Tm values for WT 
N-domain, Ndom2379, Ndom1279, Ndom389, and BSA were calculated from ellipticity plots 
monitored from 210 to 260 nm using a protein concentration of 0.04 mg/ml. Tm values are 
expressed ± standard deviation (SD).  
 
4.3.3 Kinetic characterisation of minimally glycosylated N-domain 
Since the minimally glycosylated mutant Ndom389 was likely to be a suitable 
candidate for crystallisation studies, it was important to ensure that the mutagenesis 
of the glycosylation sites did not compromise the function or structure of the enzyme. 
Analysis of the specific activities of the various glycosylation mutants gave some 
indication that the catalytic functioning of the enzyme was preserved despite reduced 
glycosylation. However, given the importance of Ndom389 for crystal structure 
determination, a more detailed kinetic analysis was performed to ensure that 
functional integrity of Ndom389 was retained, relative to glycosylation WT N-domain. 
Analysis of the kinetic parameters revealed only minor differences between 
Ndom389 and WT N-domain for the hydrolysis of Z-FHL. The Km values for WT  
N-domain were highly comparable to those of Ndom389, being 0.48 and 0.5 mM 
respectively (Figure 4.10). The kcat values for WT N-domain and Ndom389 (15.09 
and 24.32 s-1 respectively) showed a slightly higher turnover rate for the minimally 
glycosylated mutant. A comparison of the kcat/Km ratio revealed comparable catalytic 
efficiencies between the two forms, with values of 31.58 and 49.64 mM-1s-1 for WT 
and Ndom389 respectively. Previous work had put the Km of WT N-domain for the 
hydrolysis of Z-FHL at between 0.9 and 1.2 mM 159,160. While the kinetic constants 
shown here were slightly different from previous findings. This was not deemed to be 
problematic given that slightly different assay conditions were used in this study. In 




















Figure 4.10: Michaelis-Menten plot of WT N-domain and Ndom389, with kinetic 
constants Km, kcat and kcat/Km indicated. The Michaelis-Menten kinetic constants Km, kcat 
and kcat/Km were determined for WT N domain and Ndom389 using the standard ACE assay 
(see Appendix A6), except that final Z-FHL concentrations ranging from 0.00 to 2.54 mM 
were used. Assays were repeated three times in triplicate. Error bars indicate SE. 
 
4.4 Discussion 
Previous work has shown that glycosylation is important for N-domain expression 125 
as well as thermal stability 136. Here we show that the glycosylation sites required for 
expression of active protein differ from those sites which are critical to thermal 
stability. 
 
4.4.1 Identification of glycosylation sites important for expression of 
enzymatically active N-domain 
Reintroducing one or more C-terminal sites into an inactive hypoglycosylated variant 
was sufficient to restore the expression of active N-domain, as seen with 
Ndom1234569 and Ndom123789, Ndom12379 and Ndom1237. This indicates that 
C-terminal glycosylation is crucial for expression of N-domain proteins in CHO cells. 
These data also seem to indicate that there may be an element of redundancy with 

















inactive mutants when reintroduced. The removal of individual N-terminal sites 1, 2 
and 3 had no major effect on the expression of Ndom2379, Ndom1379 and 
Ndom1279, indicating that, at least individually, these sites were not critical for the 
production of active protein. These findings agree with the hypothesis that C-terminal 
glycosylation is the major contributor to effective folding and processing of the 
enzyme. However, Ndom79 and Ndom89 were not active, while Ndom789 and 
Ndom389 were. This would suggest that there is a requirement for glycosylation of at 
least three sites, and that while some of these sites must be toward the C-terminal 
region of the sequence, glycosylation of an N-terminal site is able to compensate for 
the absence of glycosylation at one of the three C-terminal sites. The location of the 
three C-terminal sites 7, 8 and 9, as well as the N-terminal site 3, does not 
immediately suggest a mechanism underlying their importance, as they are not 
clustered in a single region, but rather they are located at positions distant from one 
another (Figure 4.11). This is not surprising, however, given the various roles that  
N-linked glycosylation plays in the folding process (see Chapter 1.2.3). It is 
interesting to note the preference for C-terminal glycosylation of the N-domain, 
particularly in light of the fact that the C-domain (tACE) requires N-terminal 
glycosylation for the expression of active protein 122. A number of other proteins, 
such as butyrylcholinesterase and chondromodulin-I, also show an N-terminal 
requirement for N-linked glycans 89,161, a finding corroborated by a study on 
glycosylation sequon usage which found that distance from the C-terminus affects 
the likelihood of glycosylation of a particular sequon 63. While the N-domain has a 
preference for C-terminal glycosylation, both N- and C-terminal glycosylation sites 
have been shown to be glycosylated (see Chapter 2.4). Thus, while N-terminal 
glycosylation of proteins is generally preferred, this does not necessarily preclude 
the fact that C-terminal glycan sites may also be important in some cases. Another 
factor to consider is that the N-domain is not expressed as a single unit in vivo, but 
rather occurs as part of the larger two-domain sACE. Indeed, results have shown 
that glycosylation of sACE was preferentially located on the N-domain, with 5 of the 




















Figure 4.11: Surface representation of the N-domain of ACE indicating the location of 
glycosylation sites 3, 7, 8 and 9. N- and C-termini are highlighted in blue and red 
respectively. Glycosylation sites are numbered. Figures were drawn with PyMOL v0.92 using 
the PDB structure 2C6N 139 (DeLano Scientific, San Carlos, CA, USA). 
 
4.4.2 The effect of glycosylation on the thermal stability of the N-domain 
The different N-domain glycosylation variants can be broadly placed into two groups 
with respect to thermal stability. The first group consists of mutants which retained a 
high level of thermal stability, namely Ndom123469, Ndom123789, Ndom12379, 
Ndom1237 and Ndom2379. The second group comprises those mutants which 
displayed a marked decrease in thermal stability, namely Ndom1379, Ndom1279, 
Ndom389 and Ndom789. While the most interesting findings lie with those mutants 
comprising the second group, some deductions can be made about the contribution 
of certain glycan sites from the first group. Firstly, the removal of sites 4, 5 and 6 had 
virtually no effect, with the thermal stability of Ndom123789 being comparable to that 
of WT N-domain. This indicates that these glycosylation sites are not involved in 
conferring thermal stability to the N-domain. Secondly, the absence of site 8 (N416) 
in Ndom12379, Ndom1237 and Ndom2379 or sites 7 and 8 (Ndom1234569) resulted 
in a slight decrease in stability (Figure 4.6), indicating that these two sites play a 


















The second group contains those variants where the removal of glycan sites caused 
a marked loss of thermal stability (namely Ndom1379, Ndom1279, Ndom389 and 
Ndom789). The major characteristic distinguishing these variants from their more 
stable counterparts is the removal of either site 2 (N25) or site 3 (N45), or both sites 
2 and 3. These data clearly highlight the critical importance of these two N-terminal 
sites in maintaining thermal stability of the N-domain. Glycosylation sites 2 and 3 are 
located on α-helix two, which forms part of the lid region of the protein. It has been 
noted that glycosylation sites are often located at positions where the secondary 
structure changes 50. The active site entrance channel in the crystal structure of both 
domains is not large enough to allow substrate entry, thus necessitating some 
degree of movement within this region 162. Modelling of the C-domain structure to 
open and closed conformations of an ACE homologue, ACE2, which has been 
shown to adopt a catalytically important hinge movement upon substrate binding, 
revealed a number of potential hinge movements in the C-domain 162. Due to the 
structural similarity between the two domains, it has been proposed that both 
domains of sACE also undergo a hinge movement to allow substrate access to the 
active site 162. The location of the main hinge movements were mapped to the 
regions 98 to 125, 400 to 409 and 569 to 578 of the C-domain 162. These regions 
correspond to the N-domain residues 70 to102, 378 to 386 and 546 to 554 
respectively (Figure 4.12). Interestingly, the glycosylation sites 1 to 4 on the  
N-domain are located on the lid region, which is thought to undergo a conformational 
change during the proposed hinge movement 140. Furthermore, site 2 is located 
adjacent to the two main hinge regions. Glycosylation sites 1 and 4 did not have an 
effect thermal stability, however, it is possible that sites 2 and 3 are involved in 
stabilizing interactions involving the lid region and those areas undergoing hinge 




















Figure 4.12: N-domain structure showing the location of the proposed hinge 
movement and the glycosylation sites on the lid region. Glycosylation sites are labelled 
and indicated in orange. Lid helices shown in blue. Regions involved in the proposed hinge 
movements of are marked in r d. The N-terminal region of the N-domain is shown in purple. 
Figures were drawn with PyMOL v0.92 using the PDB structure 2C6N and 1O86 138,139 
(DeLano Scientific, San Carlos, CA, USA). 
 
The N-domain has a reported Tm of about 70 °C 
104,136, yet we determined the Tm to 
be slightly lower. Since the BSA control reported a Tm consistent with literature 
values, it is unlikely that this difference is due to instrumental or handling error. 
However, the trend of reduced glycosylation corresponding to a decrease in thermal 
stability, as well as the importance of sites 2 and 3, is strongly evident in these data, 
further confirming the results from the thermal denaturation assays. Interestingly, 
minimally glycosylated C-domain (tACEg13) has a Tm of 43 °C 
136, virtually identical 
to that of minimally glycosylated N-domain (Ndom389) 42.7 °C. Given the high 
degree of sequence and structural identity between the two domains, it is possible 

















resulting from factors other than glycosylation. These findings further highlight the 
significant role of glycosylation with respect to the thermal stability of ACE. 
 
It has previously been suggested that the marked difference in thermal stability 
between the N- and C-domains (15 °C) is attributable to the fact that the N-domain 
has a greater number of α-helices and a greater degree of glycosylation and an 
increased proline content over the region D29 to T133, as compared to the 
corresponding region of the C-domain 104. Recent work has shown that the N-linked 
glycans of the C-domain contribute significantly to its thermal stability, while in 
contrast, the presence of O-linked glycans had no effect 136. While the increased 
number of α-helices and the greater degree of proline content of the N-domain, over 
the region D29 to T133, may play a role in conferring thermal stability, we have 
shown that surface glycosylation is the major determining factor with regard to the 
greater level of thermal stability of the N-domain. This may be due to a greater 
degree of glycan site occupancy for the N-domain, about 90%, compared with 50 to 
85% for the C-domain. However, Voronov et al. (2002), also mention that the greater 
degree of glycosylation on the N-domain over the region D29 to T133 (six sites, as 
opposed to three for the C-domain) is also likely to be an important factor. Our 
findings show that while glycosylation of this region is indeed the primary factor 
causing the increased level of thermal stability for the N-domain, it is in fact the 
presence of glycosylation at sites 2 (N25) and 3 (N45) that is critical for the high level 
of thermal stability of the N-domain and not that of the entire D29 to T133 region. 
This finding is further highlighted when one considers that the loss of either of these 
two sites effectively reduces the thermal stability of the N-domain by 8 °C (Figure 
4.9). 
 
4.4.3 Kinetics characterization of minimally glycosylated N-domain 
As mentioned previously deglycosylation often has little or no effect on enzyme 
catalysis (see Chapter 1.2.3.3.). Previous work has shown that this was indeed the 
case with enzymatically deglycosylated C-domain (tACE) 124, as well as for a range 
of C-domain glycosylation mutants generated by site-directed mutagenesis, which all 
exhibited similar catalytic efficiencies for the ACE substrate hippuryl-L-histidyl-L-
leucine (HHL), when compared with WT C-domain 122. Kinetic studies on Ndom389 

















affinities and also have similar catalytic efficiencies for the ACE substrate Z-FHL. 
Thus, glycosylation does not appear to have an effect on the kinetic properties of 
either the N- or C-domain. 
 
4.4.4 Crystallisation of minimally glycosylated N-domain 
The use of a hypoglycosylated form of a protein to enable reproducible crystallization 
has been shown to be an effective approach in a number of cases 89,122,163,164. 
However, reduced glycosylation can translate to reduced stability and Ndom389 has 
been shown to be relatively unstable as compared to the WT form. However, its 
thermal stability was sufficient to justify its use in crystallization trials, typically carried 
out at 16 °C. Recent crystallization trials with this variant have shown that it is able to 
crystallize reproducibly, with crystals forming in multiple wells of the crystallization 
screening plate, the best of which diffracted to 2 Å 123. It is often a concern that 
introducing mutations may affect the structure of the protein, which would be 
problematic for this approach to crystal structure determination. However, the 
kinetics of the minimally glycosylated mutant are similar to the WT form, which would 
imply that a structural determination of Ndom389 is likely to be highly informative of 
the structure of WT N-domain. Furthermore, aligning the structures of WT N-domain 
and Ndom389 in PyMOL v0.92 (Figure 4.13), revealed an RMSD of 0.56 Å for all 
atoms. Given that the structures were solved to a resolution of approximately 2 Å, 





















Figure 4.13: Comparison of the NB-DNJ and minimally glycosylated crystal structures 
of the N-domain. Density corresponding to GlcNac residues at sites N45, N416 and N480 
are indicated in orange on the Ndom389 structure, the N-domain selective inhibitor RXP407 
(yellow) bound to the active site zinc (grey) of Ndom389 is shown. N- and C-termini 
highlighted in purple and red respectively. Figures were drawn with PyMOL v0.92 using the 
PDB structures 2C6N 139 and 3NXQ 123 (DeLano Scientific, San Carlos, CA, USA). *The 
crystallisation and solution of the Ndom389 structure was carried out by R. Acharya’s 
research group (University of Bath, UK). 
 
4.4.5 Conclusions 
This study has revealed that C-terminal glycosylation sites are required for the 
expression of active N-domain proteins, while N-terminal sites are critical for 
maintaining thermal stability. It is interesting that different glycosylation sites are 
involved in these key roles. This is likely due to different selective pressures acting 
on the different glycosylation sites. Glycosylation sites required for expression may 
be selected for based on the degree to which they facilitate lectin-chaperone binding, 

















folding in the ER 78-80. Those sites involved in thermal stability (sites 2 and 3) are 
most likely to be selected for based on their ability to stabilize catalytically and 
structurally important regions of the protein, such as the proposed flexible hinge 
region of ACE. We have shown that reduced glycosylation does not greatly affect the 
kinetics of the enzyme and that producing a minimally glycosylated variant of the  
N-domain is an effective means of obtaining a form of the protein suitable for high 
throughput crystallization studies, as evidenced by the recently solved crystal 


















Chapter 5: Cloning, expression and 






There is a drive towards the rational design of domain selective ACE inhibitors. The 
crystal structures of the individual N- and C-domains have greatly aided this effort. 
However, these structures do not give an indication as to the orientation of the two 
domains relative to one another, a factor which is important given the negative 
cooperativity between the two domains 160,165,166. In addition, the solution of the 
crystal structure of sACE would greatly benefit our understanding of the mechanism 
of the reported negative cooperativity, as well as providing insight into inhibitor-
enzyme interactions within the full-length protein. Thus far it has not been possible to 
crystallise sACE. This is likely due to the high degree of N-glycosylation present on 
the surface of the enzyme, as sACE is expected to contain glycosylation at between 
seven and eight sites, based on calculations of the mass contribution of the glycans 
to sACE 84. In addition, N-terminal sequencing of sACE has identified the presence 
of glycans at six sites, most of which were located on the N-domain 124. This would 
suggest that the glycosylation state of the N-domain is critical for the expression of 
active sACE.  
 
However, there is also a degree of inter-domain flexibility –the capacity for two 
domains to move relative to one another, due to the flexible linker region joining 
them 139. Both the interdomain flexibility as well the presence of extensive surface 
glycosylation are factors that could inhibit the formation of tightly packed molecules 
in a crystal lattice 109-111.  
 
While the X-ray crystal structure for sACE has yet to be determined, a low resolution 
structure using electron microscopy has been published 167. This work modelled the 
















negatively stained sACE particles. These results indicate that the domains adopt an 
extended orientation relative to one another. While these findings give some 
indication of the relative positions of the two domains, there are a few limitations to 
the study. Firstly, assignment of the N- and C-domains to the electron micrograph 
reconstructions of sACE involves a certain amount of subjectivity as the differences 
between the two domains are not clear at the achieved resolution of 2.3 nm. 
Secondly, the mechanism underlying domain negative cooperativity was not 
addressed. Thus, the solution of a sACE crystal structure is still needed to clarify the 
exact orientation of the domains and identify the mechanism of domain negative 
cooperativity.  
 
It is hoped that creating a form of sACE with minimal glycosylation will allow the 
production of a crystallisable form of the enzyme. As mentioned previously, sACE is 
expected to contain up to eight glycans, most of which are likely to be located on the 
N-domain, with only one being identified on the C-domain 84,124. This seems to 
suggest that glycosylation of the N-domain is especially important for the expression 
of sACE. Thus, we attempted to investigate whether the minimum glycosylation 
requirements for the N-domain, could be applied to sACE. To test this hypothesis, 
we decided to fuse minimally glycosylated N-domain (Ndom389) together with 
minimally glycosylated C-domain (since very little glycosylation was found on the  




1. To introduce a restriction endonuclease site into minimally glycosylated  
N- and C-domains to enable subcloning of the two domains into a single 
construct. 
2. To express, purify and characterise the minimally glycosylated sACE forms. 

















5.2 Experimental procedures 
5.2.1 Materials 
Restriction endonucleases Eco91I, EcoRI, KpnI, NotI and T4 ligase were purchased 
from Fermentas. ACE N-domain monoclonal anti-body 4G6 used to detect sACE 
was a gift from S. Danilov. 
 
5.2.2 Plasmid templates  
Previously generated minimally glycosylated mutants, Ndom389 (N-domain), and 
tACEg13 (C-domain) 122, were used as templates. tACEg13 is a soluble construct, 
lacking a transmembrane region. Soluble sACE in pcDNA3.1+ was used for 
comparison with hypoglycosylated sACE. 
 
5.2.3 Mutagenic oligonucleotides 
Primers were engineered to introduce a restriction site via the introduction of silent 




Table 5.1: Mutagenic oligonucleotides for the introduction of a restriction 
endonuclease cloning site. The introduced Eco91I restriction site is underlined. 
 
5.2.4 Site-directed mutagenesis and cloning of hypoglycosylated sACE 
Carried out as described previously (Chapter 3.2.4) 
 
5.2.5 Expression and purification of sACE glycosylation variants 
Carried out as described previously (Chapter 4.2.1) 
 
5.2.6 Enzymatic activity assay and Western blot 

















5.2.7 Thermal denaturation assay 
Carried out as described previously (Chapter 4.2.4) 
5.2.8 Determination of kinetic constants for the hydrolysis of Z-FHL 
Carried out as described previously (Chapter 4.2.6) 
 
5.3 Results 
5.3.1 Construction of minimally glycosylated sACE 
The recombinant N-domain constructs (including Ndom389) contain a sequence of 
eight amino acids at the C-terminus which overlaps with the N-terminal region of the 
recombinant C-domain constructs (including tACEg13). This region is ideal for 
joining Ndom389 and tACEg13 into a single construct, essentially creating minimally 
glycosylated sACE. However, due to a lack of unique endonuclease restriction sites 
in this region, it was necessary to introduce one via site-directed mutagenesis. Using 
the Watcut webtool (see chapter 3.2.3) it was determined that an Eco91I restriction 
site could be introduced into this region in both Ndom389 and tACEg13, without 
affecting the coding sequence. The presence of this new site would then facilitate 
subcloning of the two domains into a single minimally glycosylated construct.  
 
Successful introduction of the cloning site was observed by digestion of 
Ndom389pBSKII with KpnI and Eco91I and tACEg13pBSK with NotI and Eco91I. 
The resulting digests produced DNA fragments at approximately 2 and 3 Kb in both 




















Figure 5.1: Vector map and restriction endonuclease digest of Ndom389 and tACEg13. 
A) Ndom389 digested with KpnI and Eco91I. Lane 1 - λDNA-EcoRI/HindIII ladder, Lane 2 - 
Ndom389+Eco91I showing fragments at 2 and 3 kb, Lane 3 - Ndom389 (negative control) 
showing DNA fragment at about 5 kb. B) tACEg13 digested with NotI and Eco91I. Lane 1 - 
λDNA-EcoRI/HindIII ladder, Lane 2 - tACEg13+Eco91I showing fragments at 1.8 and 3 kb, 
Lane 3 - tACEg13 (negative control) showing DNA fragment at about 5 kb. 
 
Following successful mutagenesis, tACEg13 was subcloned into Ndom389pBSKII 
using Not I and the newly generated Eco91I restriction site (Figure 5.2 A). This full-
length minimally glycosylated sACE construct was then cloned into the mammalian 
















cloning site region. The successful cloning of Ndom389-tACEg13 into pCDNA3.1+ 
was confirmed by digestion with EcoRI and Eco91, which revealed the presence of 




Figure 5.2: Cloning strategy, vector map and restriction endonuclease digest of 
Ndom389-tACEg13 in pcDNA3.1+. A) Schematic diagram of the cloning strategy used to 
generate Ndom389-tACEg13. Relevant restriction sites and their positions indicated.  
B) Vector map and digest screen for Ndom389-tACEg13 pCDNA3.1+ digested with EcoRI 

















5.3.2 Expression and purification of Ndom389-tACEg13 in CHO cells 
Ndom389-tACEg13, referred to as minimally glycosylated sACE (mg-sACE) from 
here on, was expressed in CHO cells and found to be enzymatically active. Indeed 
purified mg-sACE reported a specific activity comparable to that of WT sACE, with 
values of 1058 and 1106 mU/mg respectively (Figure 5.4A). These findings are 
consistent with work on the individual domains which showed that kinetic parameters 
for Ndom389 (see Chapter 4.3.1) and tACEg13 122 were similar to those for the WT 
form of the two domains. 
 
The purity of mg-sACE was confirmed by SDS-PAGE, where a single band was 
observed. However, additional bands between 72 and 95 kDa and just below 72 kDa 
were also seen (Figure 5.3). Interestingly, the minimally glycosylated N-Domain 
migrates to a similar position between 72 and 95 kDa (see Chapter 4, Figure4.4), 
while minimally glycosylated C-domain migrates to just under 72 KDa 122. This 
indicates that a small portion of mg-sACE may have been cleaved at the linker 




Figure 5.3: SDS-PAGE of sACE variants stained with Coomassie brilliant blue. Lower 
molecular weight bands corresponding to the N- and C-domains are indicated.  
Lane 1 - Biorad Prescision plus protein™ standard, Lane 2 - sol sACE, Lane 3 - mg-sACE. 

















Western blot detection of purified mg-sACE was carried out using an N-domain 
specific monoclonal antibody (see Appendix A5). Immunoblotting showed that  
mg-sACE migrated to a lower position as compared with WT sACE, consistent with 
the reduced level of glycosylation of this enzyme (Figure 5.4B). Interestingly, an 
additional band was observed between 72 and 95 kDa for mg-sACE, but not for WT 
sACE. This indicates that the corresponding fragment seen in the SDS-PAGE 
(Figure 5.3) was that of the individual N-domain, and implies that the lower band 




Figure 5.4 Activity and expression of mg-sACE and WT sol sACE. A) Specific activity of 
sACE glycosylation variants. Error bars indicate SE. B) Western blot of purified recombinant 
sACE proteins, probed with an anti-N-domain monoclonal antibody (4G6), Spectra™ broad 

















5.3.3 Kinetic characterisation of mg-sACE 
The kinetic parameters governing the hydrolysis of the substrate Z-FHL by sACE 
were determined for soluble sACE as well as for mg-sACE. Determination of the 
binding constants revealed identical Km’s, with both forms reporting values of 0.15 
mM (Figure 5.5). These findings are consistent with those previously determined for 
sACE where a Km of 0.16 mM was reported 
159. Furthermore, it was found that the 
turnover number and catalytic efficiency  of WT sACE and mg-sACE were also highly 
comparable, with kcat values of 13.19 and 13.90 s
-1 and kcat/Km values of 86.39 and 




Figure 5.5: Michaelis-Menten plot of WT sACE and mgsACE, with kinetic constants Km, 
kcat and kcat/Km indicated. The Michaelis-Menten kinetic constants Km, kcat and kcat/Km were 
determined for soluble sACE and mg-sACE using the standard ACE assay (see Appendix 
A6), except that final Z-FHL concentrations ranging from 0.00 to 2.54 mM were used. 

















5.3.4 The effect of glycosylation on the thermal stability of sACE 
The effect of reduced glycosylation on the thermal stability of sACE was assessed 
using the thermal inactivation assay mentioned previously (Chapter 4.2.4). Thermal 
inactivation of WT sACE showed that the enzyme was moderately stable, as 
compared with the highly stable WT N-domain, retaining approximately 20% activity 
after 30 min thermal inactivation (Figure 5.6), consistent with previous findings 136. 
Minimally glycosylated sACE however, showed much reduced thermal stability, 
retaining 20% activity after only 5 min and reaching complete inactivation after 
approximately 15 min thermal denaturation. Not surprisingly, the thermal stability 
profile of mg-sACE was virtually identical to that of the minimally glycosylated  




Figure 5.6: The effect of glycosylation on the thermal stability of sACE and mg-sACE 
as compared to the N-domain and Ndom389. Percentage residual activity as a function of 
time at 55 °C was determined by enzymatic assay using the ACE substrate Z-FHL (see 
Appendix A6). Error bars indicate SE.  
 
5.4 Discussion 
5.4.1 Cloning, expression and kinetic characterisation of minimally 
glycosylated sACE 
The generation of a soluble sACE variant with minimal glycosylation was 
















Ndom389, in frame with the minimally glycosylated C-domain mutant, tACEg13. In 
this way, a sACE form containing only five functional glycosylation sequons, out of a 
potential 17, was produced. The expression of this mg-sACE variant in CHO cells 
resulted in the production of active enzyme. This indicates that the folding 
requirements (in terms of glycosylation) of full-length sACE are at least equal to the 
sum of those for the individual domains. Given that Yu et al. (1997) report that most 
of the surface glycosylation on sACE was on the N-domain, it is likely that the 
minimum glycosylation requirements for the expression of active N-domain are a 
major determining factor in producing an active form of minimally glycosylated sACE. 
Furthermore, mg-sACE and WT sACE displayed identical kinetic constants (Km, kcat 
and kcat/Km) indicating that the presence, or absence, of the majority of glycans on 
surface of sACE does not affect its primary catalytic functioning. Thus, by inference, 
the structure of the two forms, particularly with regard to the active site residues, is 
likely to be highly similar. This would imply that a structural determination of  
mg-sACE is likely to be representative of WT sACE. 
 
5.4.2 The effect of glycosylation on the thermal stability of sACE 
While glycosylation did not affect the activity or kinetic constants of the enzyme, it did 
have a major affect on its thermal stability. The thermal stability of sACE was found 
to be consistent with previous findings 136, retaining roughly 20% activity after 30 min 
thermal inactivation. This was a comparable level of thermal stability to that of WT 
tACE, yet somewhat lower than that of WT N-domain which retains 80% activity over 
the same period. However, the thermal stability of tACE was determined by 
inactivation at 50 °C, while thermal denaturation of N-domain and sACE in this study 
was carried out at 55 °C. This would indicate that sACE is in fact more stable than 
the individual C-domain (tACE), while still being notably less stable than the  
N-domain. Thus, the stability of sACE is likely between that of the N- and C-domains. 
The stability of mg-sACE was much lower than that of WT sACE, retaining only 20% 
activity after just 5 min of thermal inactivation, making the level of thermal stability of 
mg-sACE identical to that of the individual minimally glycosylated N- and C-domains 
(Ndom389 and tACEg13). This is hardly surprising, however, since mg-sACE is in 
fact made up of the minimally glycosylated domains Ndom389 and tACE13, which 

















5.4.3 Crystallisation trails on mg-sACE 
Minimally glycosylated sACE was submitted for crystallisation trials, which were 
carried out by our collaborator, R. Acharya’s research group (Bath, UK). However, 
mg-sACE has thus far not produced diffractable crystals under a variety of conditions 
tested. This could imply that reducing glycan complexity alone is not sufficient in this 
case, and that inter-domain flexibility may also be a significant factor regarding the 
inhibition of tight crystal packing. To this end, the introduction of a cysteine residue 
into the linker region may facilitate the formation of a novel disulfide bridge, which in 
turn may be effective in stabilising the protein by restricting the inter-domain flexibility. 
However, it is, unlikely that this approach will be successful on its own, but 
introducing this disulfide bridge into a minimally glycosylated sACE variant may well 
be a more successful approach. 
 
Alternatively, the failure of mg-sACE to form crystals could also be due to the 
presence of heterogeneous sACE populations. Non homogenous protein populations 
are not ideal for crystallisation experiments as these rely on multiple units of the 
same molecule arranging themselves in a highly ordered fashion 109-111. SDS-PAGE 
and Western blot analysis revealed the presence of protein fragments at sizes 
comparable to those of the minimally glycosylated N- and C-domains. This is likely to 
have a negative effect on mg-sACE crystallisation. The cleavage of sACE at the 
linker region joining the two domains has been reported previously 7,8. Previous work 
comparing glycosylated and unglycosylated two-domain cellulases reported that the 
two variants were similar in most characteristics, except that the glycosylated form 
was found to be resistant to interdomain cleavage, where the unglycosylated form 
was not 168. Thus, it is possible that the reduced level of surface glycosylation in mg-
sACE allows for an increased level of cleavage at the linker region, effectively 
resulting in a greater proportion of the sACE population occurring as individual 
domains. Examination of the N- and C-domain crystal structures revealed that two N-
linked glycosylation sites on each domain were located close to the linker region. 
These include sites 6 and 9 for the N-domain and sites 2 and 3 for the C-domain 
138,139. Since only two of the four sites are present in our construct (site 9 on the N-
domain and site 3 on the C-domain), the missing glycans may be responsible for 

















However, a short term solution to this problem, in terms of solving the sACE crystal 
structure, would be to selectively elute only the full length sACE during the protein 
purification step. Chen et al. (2010) report that they were able to separate individual 
N- and C-domains from a sample containing full length sACE by altering the buffer 
and pH during elution from the sepharose-lisinopril affinity column. According to their 
strategy, it was possible to elute the N- and C-domains with 20mM Mes-NaOH (pH 6) 
and 20 mM HEPES (pH 6) respectively, before finally eluting the remaining full 
length sACE proteins with 50 mM borate (pH9.5). The selective elution of full length 
mg-sACE may result in an improved outcome for crystallisation trials on this enzyme. 
 
It is interesting to note that the kinetic constants of mg-sACE were comparable to 
those of sACE, despite the increased level of cleavage in the linker region producing 
a sub population of individual N- and C-domains. One reason for this is that although 
a portion of mg-sACE appears to be cleaved into its individual domains, it is likely 
that these domains remain active 7,8,167. Thus, the individual domains are still able to 
contribute to substrate cleavage. In addition, the proportion of mg-sACE molecules 
cleaved to the individual domains, while large enough to potentially inhibit 





















Conclusions and future work 
 
 
Mass spectrometry based profiling of the glycosylation site occupancy of the  
N-domain glycosylation sequons revealed that all of the potential glycosylation sites 
on the N-domain do in fact carry glycosylation, with the exception of site 10 (N494). 
Site 10 was not expected to be glycosylated given that it is not located on the 
surface, but buried in the protein, as well as the fact that its Asn-Xaa-Ser/Thr sequon 
is followed by a Pro, a factor known to prevent glycosylation of a particular sequon 56.  
 
Furthermore, we have determined that glycosylation of the C-terminal region of the 
N-domain is critical for expression of active protein, and that the presence of three  
C-terminal glycans is sufficient for expression of active protein. While we found that 
the presence of at least three C-terminal glycosylation sites were necessary for the 
expression of active protein, we also discovered that there was some redundancy 
with regard to which sites were necessary. This is based on our finding that an  
N-terminal site (site 3) was able to compensate for the loss of glycosylation at a  
C-terminal site, such that both the Ndom789 and Ndom389 glycosylation mutants 
were enzymatically active. 
 
Recent reports have shown that glycosylation contributes significantly to the thermal 
stability of the C-domain of ACE 136. Our findings indicate that the thermal stability of 
the N-domain is also significantly affected by the presence of surface glycosylation, 
with decreased levels of glycosylation corresponding to decreased thermal stability. 
Moreover, the presence of glycosylation at sites 2 and 3 are critical for the 
maintenance of high levels of thermal stability, with a loss of glycosylation at either 
site proving severely detrimental to the thermal stability of the N-domain. 
 
In contrast to its critical role in thermal stability, glycosylation appeared to have little 
or no effect on the enzymatic activity of the N-domain, with specific activities being 
similar between the various glycosylation mutants and the WT protein. Furthermore, 

















The identification of the minimum glycosylation requirements for the production of 
active N-domain has led to the generation of an N-domain variant that is able to 
crystallise in a reproducible manner, which was previously not achievable. The value 
of having a readily crystallisable form of the N-domain cannot be overstated, as it 
allows high throughput inhibitor-enzyme crystallisation studies. Indeed, the crystal 
structure of the minimally glycosylated N-domain variant (Ndm389) has been solved 
in the presence of an N-domain selective inhibitor (RXP407) 123. This structure 
provides further insight into the binding interactions that contribute to the domain 
selectivity of this inhibitor, as well as demonstrating the effectiveness of this 
approach for the crystallisation of glycoproteins.  
 
The fact that mg-sACE was expressed in an active form revealed that the 
glycosylation requirements for full length sACE were at least equal to the sum of the 
requirements for the two individual domains. Previous findings indicate that the 
majority of the glycans on sACE are located on the N-domain 112,124. Thus, it may 
well be that the glycosylation requirements for the expression of sACE are 
determined by the glycosylation requirements of the N-domain.  
 
While glycosylation is important for the expression of active sACE, its effect on the 
catalytic functioning of the enzyme was found to be negligible since both soluble 
sACE and mg-sACE had similar binding affinities, turnover rates and catalytic 
efficiencies for the hydrolysis of Z-FH. Although the minimally glycosylated form of 
sACE retained its catalytic properties, the reduced level of protein glycosylation 
resulted in a marked decrease in thermal stability and was also most likely 
responsible for the increased level of cleavage in the linker region of mg-sACE.  
 
The mg-sACE variant has thus far not been able to produce crystals under the 
conditions tested, indicating the need to revisit the design of the minimally 
glycosylated sACE variant. Given the high degree of thermal stability of Ndom2379 
(Chapter 4.3.2), it may be worthwhile generating a minimally glycosylated sACE 
variant using this N-domain glycoform, in an attempt to increase its thermal stability. 
Additionally, generating N-domain variants Ndom237, Ndom238 and Ndom239 for 
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proteins with increased stability, yet having only a few intact glycosylation sites. As 
mentioned in Chapter 5.4.2, the introduction of a novel disulfide bridge into the linker 
region of such a glycosylation variant of sACE, may result in a thermally stable, 
minimally glycosylated variant which also has reduced inter-domain flexibility. This 
approach targets three important factors currently hampering the crystallisation of 
sACE, and is an ideal candidate to enable the solution of the presently elusive sACE 
crystal structure. However, while reduced glycosylation, increased thermal stability 
and reduced interdomain flexibility are important constraints, the presence of an 
increased level of proteolytic cleavage at the linker region joining the two domains of 
mg-sACE is a matter that must be addressed. Given that sites 6 and 9 on the  
N-domain, and sites 2 and 3 on the C-domain, are located in close proximity to the 
linker region, including these sites in a minimally glycosylated sACE mutant may 
restore protection against the proteolytic cleavage of the linker region. 
 
Finally, this work has resulted in the creation of a number of N-domain constructs 
with varying degrees of intact glycosylation sequons. A similar group of C-domain 
mutants has previously been generated 122. Combining the N- and C-domain 
glycosylation variants, through the cloning strategy used to make mg-sACE, will 
result in the creation of a library of sACE glycosylation mutants. These sACE 
glycosylation mutants would be a useful resource to investigate the effects of 
glycosylation on protein-protein interactions, such as ACE dimerisation and the 
proposed link between glycan mediated dimerisation and the biological process of 






















Figure A1: Amino acid sequence of recombinant N-domain. Signal peptide targeting the 
enzyme for secretion is underlined (not present in the mature form of the enzyme). N-linked 

























Figure A3: Representative SDS-PAGE gels stained with Coomassie, showing 
successful purification of ACE N-domain proteins. Lane 1 - Biorad Prescision plus 
protein™ standard. Lane 2 - WT N-domain, Lane 3 – Ndom1234569, Lane 4 – Ndom12379, 
Lane 5 – Ndom1279, Lane 6 – Ndom1237, Lane 7- Ndom389. N-domain variants migrated 





Figure A4: Circular dichroism spectra of BSA variants showing temperature induced 
denaturation. Unfolding transitions for WT N-domain, Ndom2379, Ndom1279 and Ndom389 

















A1. Preparation of competent E.coli DH5α cells 169 
An over-night culture of E.coli DH5α cells was inoculated into 50 ml of Luria broth 
(LB) (1% (w/v) tryptone; 5% (w/v) yeast extract; 0.17 M NaCl) and incubated at 37 °C 
until an OD595 of between 0.4 and 0.6 was reached. The culture was chilled on ice 
for 15 min. Cells were then collected by centrifugation at 6000 RPM for 5 min. The 
cell pellet was resuspended in 1/10 original volume of pre chilled TFBI (30 mM KOAc; 
100 mM RbCl; 10 mM CaCl2; 50 mM MnCl; 15% (v/v) glycerol; adjusted to pH 5.8 
with glacial acetic acid). The resuspended cells were incubated on ice for 15 min 
before centrifugation at 6000 RPM for 5 min. The cell pellet was resuspended in 1/25 
original volume of pre-chilled TFBII (10 mM MOPS; 10 mM RbCl2; 75 mM CaCl; 15% 
(v/v) glycerol; adjusted to pH 6.5 with glacial acetic acid). The final resuspension was 
divided into 100 µl fractions and stored at -80 °C until use. 
 
A2. Transformation of competent cells 169 
50 to 100 ng plasmid DNA was added to 100 µl of prepared competent cells were 
thawed on ice. The DNA-competent cells mixture was incubated on ice for at least 
25 min before heat shock of 42 °C for 0.5 min. Heat shocked, cells were immediately 
placed on ice for 1 min, following which 900 µl LB was added to the cells. 
Transformed cells were grown at 37 °C for 60 min with shaking. 100 µl of the 
transformation was plated on Luria agar plates (1.2% (w/v) agar, 1% (w/v) tryptone; 
5% (w/v) yeast extract; 0.17 M NaCl) containing 50 µg/ml ampicillin. 
 
A3. Restriction enzyme digestion 
Restriction enzyme digests were carried out in 20 μl reactions on 3 μl crude DNA 
preparation or 500 ng purified DNA, for 90 min at 37 °C. Relevant reaction buffers at 
1x or 2x concentration were used as per the manufacturers instruction. Restriction 
enzymes were used at between 1 and 10 units per reaction, according to the 
manufacturers guidlines. 
 
A4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 170 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as per 
standard laboratory protocols. Briefly, 20 µl of sample was mixed with 5 µl 5x sample 
















0.25% (w/v) bromophenol blue) and denatured at 100 ˚C for 5 min. Denatured 
samples were separated on 10% polyacrylamide gels made up in TBE buffer (89 mM 
Tris base, 89 mM boric acid, 2 mM EDTA) with 0.1 % (w/v) ammonium persulphate 
(AMPS) and 10 µl tetramethylethylenediamine (TEMED). Electrophoresis was 
carried out at 25 mA/gel for 1 hr.  
 
A5. Immunoblotting of purified proteins 169 
Following protein separation by SDS-PAGE, proteins were transferred to Hybond™-
ECL nitrocellulose membranes (Amersham, Buckinghamshire, UK) in Blotting buffer 
(0.5 M Tris, 1.44% (w/v) glycine, 0.2% (v/v) methanol) at 100 V for 1 hr, using the 
wet gel transfer method. Membranes were incubated in 1x TBST (50 mM Tris-HCl 
pH 7.4, 0.2 M NaCl, 0.1% (v/v) Tween-20) containing 5% skim milk for 1 hr with 
shaking, to block unoccupied binding sites and prevent non-specific binding during 
the antibody incubation steps. Membranes were incubated in rat anti-ACE primary 
antibody (4G6) (kind donation from S. Danilov) diluted 1:200 in 1x TBST containing 
5% skim milk for 1.5 hrs. Unbound antibody was removed by washing 3x 5 min with 
1x TBST. Membranes were incubated in goat anti-rat peroxidase-conjugated 
secondary antibody, diluted 1:2000 in 1x TBST containing 5% skim milk for 1 hr. 
Unbound antibody was removed by washing 3x 5 min with 1x TBST. ACE was 
detected using the ECL Plus Western Blot Detection kit (Amersham) and visualised 
on a G:Box iChemi™ chemiluminescence imager (Syngene, Cambridge, UK) and 
analysed using the GeneSnap™ software package (Syngene). 
 
A6. ACE activity assay 171,172 
A6.1 Z-FHL working solution 
A 20 mM stock solution of Z-FHL was prepared by dissolving 220 mg Z-FHL in 2 mL 
0.28 M NaOH, and made up to 20 mL with dH2O. The 1 mM Z-FHL working solution 
was made up by adding 15 ml dH2O to 4 ml 5x phosphate buffer (0.5 M potassium 
phosphate, pH 8.3, 1.5 M NaCl) with 20 µl 10 mM ZnSO4, lastly 1 ml of 20 mM Z-
FHL was added. 
 
A6.2 Hippuryl-His-Leu standard curve  
Hippuryl-His-Leu (HL) standards were prepared from a 5.7 mM stock solution in 1x 
















nmoles/ l HL. 35 l of each standard were added to a 96-well fluorometric plate in 
triplicate. To this, 120 l 0.4 N NaOH was added. HL was derivatised by the addition 
of 10.0 l 20mg/ml O-pthaldialdehyde and incubated for 10 min. Derivatisation was 
terminated by the adition of 30.0 l 3N HCL. 
 
A6.3 Z-FHL activity assay 
Assays were carried out, using three sets of triplicate repeats for each sample. 
Briefly, 30 µl Z-FHL working solution was aliquoted into a 96 well plate and pre-
incubated to 37 °C. To this, 5 µl sample (pre warmed to 37 °C) was added, and the 
reaction incubated at 37˚C for 15 min to allow enzymatic cleavage of the Z-FHL 
substrate (no sample was added to the blank-time-zero (BZT)). Enzymatic cleavage 
was stopped by the addition of 120 µl 0.4 M NaOH and 5 µl sample was added to 
the BZT. Cleaved HL product was derivatised by the addition of 10 µl  
O-phthaldialdehyde (20mg/ml in methanol). Derivatisation was terminated after 10 
min by the addition of 3N HCl. Fluorescence of the 195 µl of reaction was measured 
at excitation-emission wavelengths of Ex=360 nm and Em=485 nm, on a Cary 
Eclipse fluorimeter (Varian, CA, USA). The measured fluorescence readings were 
converted to activity (mU) using the HL standard curve (Figure A5). ACE activity (mU) 




















Figure A5: HL standard curve showing correlation between fluorescence intensity and 
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